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INTRODUCTION
Pharmaceutical innovation has generated tremendous benefits for human
health.1 Prescription drugs can reduce suffering, prevent surgeries and
hospitalization, save lives, and permit individuals to live more productive
and fulfilling lives.2 Prescription drugs have also been shown to decrease
the cost of hospitalization. 3 Those who need but cannot afford prescription
medication risk the continuation or worsening of symptoms, development
of complications, and loss of productivity including missed work days and
potential dismissal, as well as preventable pain, disability, and death.
Federal legislation to improve the affordability of pharmaceuticals
includes the Medicare Prescription Drug, Improvement, and Modernization
Act of 2003, 4 which launched the Medicare Part D prescription drug
* At the time of writing, Assistant General Counsel, American Dental Association; B.A.,
University of Notre Dame; J.D., The University of Michigan; LL.M., Loyola University
Chicago School of Law; former Corporate Legal Counsel, Armstrong International, Inc. The
views expressed in the article are the author's and do not reflect the official policy or
position of the American Dental Association or any other organization. I would like to
acknowledge the support of Lawrence Singer, Director of the Beazley Institute for Health
Law and Policy at Loyola University Chicago School of Law, Leatrice Berman Sandler,
Elizabeth Cepero, and Todd Stankewicz of the Centers for Medicare & Medicaid Services
(CMS), Bernadette M. Broccolo and Joan Polachek of McDermott Will & Emery, James C.
Dechene of Sidley Austin LLP, Frank A. Dodge, R.Ph., HRSA Pharmacy Services Support
Center, Joshua Golden of Hewitt Associates LLC, Monique M. Karaganis, M.D., Gordon
Schiff, M.D., Associate Director, Center for Patient Safety Research and Practice, Division
of General Internal Medicine, Brigham and Women's Hospital and Associate Professor of
Medicine at Harvard Medical School, and Richard G. Ziegler of Mayer Brown.
1. Scott Gottlieb, Deputy Comm'r for Med. & Scientific Affairs, Food & Drug Admin.,
Speech at the Thirtieth International Good Manufacturing Practices Conference (Mar. 14,
2006) (transcript available at http://www.fda.gov/oc/speeches/2006/gmp0314.html).
2. Id.
3. Robert I. Field, Handbook of Pharmaceutical Public Policy, 29 J. LEGAL MED. 255,
255 (2008) (book review); Bruce C. Stuart et al., Assessing the Impact of Drug Use on
Hospital Costs, 44 HEALTH SERVICES RESOURCES 128, 137 (2009).
4. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L.
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program to help elderly and disabled Americans afford prescription drugs.5
The Drug Price Competition and Patent Term Restoration Act (the "Hatch-
Waxman Act")6 facilitated market entry by manufacturers of generic
pharmaceuticals while incenting research-based ("innovator")
pharmaceutical companies to develop new innovative brand-name drugs.7
State legislation to improve access to prescription drugs includes initiatives
that lower drug prices for elderly and low-income individuals, purchasing
pools that drive volume discounts from pharmaceutical manufacturers, and
drug importation programs that enable state residents to purchase drugs
from abroad. 8
Despite existing initiatives, a significant number of American consumers
do not or can not access the prescription drugs they require. In 2007, a
reported 36.1 million working-age adults and children went without
medication due to concerns over cost, an 11.7 million increase from 2003.9
Many of these individuals lack insurance, while others are underinsured
with health plans that either does not cover the outpatient prescription drugs
they need or impose cost-sharing at levels they cannot afford.10
Affordability problems may also stem from higher prescribing rates and
increasing drug prices, particularly for new medications."
Part I of this article discusses advances in prescription medication and its
importance in the health care system. In the past one hundred years,
pharmaceuticals have revolutionized medical care. Prescription drugs are
now available to alleviate symptoms and to help cure or manage diseases
that in the recent past were disabling or fatal.
Part II analyzes access to pharmaceuticals in the United States.
Individuals covered by various health plans and programs, and those who
have no prescription drug coverage, pay significantly different prices for the
same medications. Factors influencing access include public and private
assistance programs and discounted prices for certain generic
No. 108-173, 117 Stat. 2066 (2003).
5. See Medicare.gov, Prescription Drug Coverage, http://www.medicare.gov/
pdphome.asp (last visited Sept. 9, 2009).
6. See generally Drug Price Competition and Patent Term Restoration Act of 1984, Pub.
L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended at 21 U.S.C. § 355 (1994)).
7. Sarah E. Eurek, Hatch- Waxman Reform and Accelerated Market Entry of Generic
Drugs: Is Faster Necessarily Better?, 2003 DuKE L. & TECH. REv. 0018, 2 (2003).
8. Nat'l Conference of State Legislatures, 2008 Prescription Drug State Legislation,
http://www.ncsl.org/IssuesResearch/Health/2008PrescriptionDrugStateLegislationNCSL/tabi
d/14418/Default.aspx#Map (last visited Nov. 15, 2009).
9. LAURIE E. FELLAND & JAMES D. RESCHOVSKY, CTR. FOR STUDYING HEALTH SYS.
CHANGE, MORE NONELDERLY AMERICANS FACE PROBLEMS AFFORDING PRESCRIPTION DRUGS
1 (2009), http://www.hschange.com/CONTENT/1039/1039.pdf
10. Id.
11. Id.
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pharmaceuticals by discount stores and chain pharmacies.
Part III describes the pharmaceutical industry and its role in the health
care system. Innovator pharmaceutical manufacturers research, develop and
test new drugs, obtain patent protection, secure approval from the Food and
Drug Administration (FDA), and then market and promote their product to
physicians, pharmacists, and consumers. These manufacturers strategically
price and seek reimbursement status to maximize returns on their
investment. The Hatch-Waxman Act encourages generics manufacturers to
develop products that are equivalent to brand-name drugs, to rely on the
innovator's research to secure FDA approval through a less burdensome
procedure, and to challenge the innovator's patents with the goal of
marketing generic versions of patented drugs prior to the patent expiration
date.
12
Part IV explores industry trends that affect access. Trends affecting
pharmaceutical manufacturers include the numerous drug patents that will
expire before 2016 (the "patent cliff') and the paucity of new drugs in the
developmental "pipeline." Other trends influencing manufacturers include a
slowdown in the growth of demand for prescription drugs, financial
problems due to the current economic crisis, a potential increase in liability
for pharmaceutical products that harm consumers, and an increase in
mergers and acquisitions, particularly involving biotechnology companies
and products. Drug manufacturers are threatened by developments in
personalized medicine because genetic testing for drug effectiveness could
lead to smaller market share for their products. A similar threat is posed by
comparative effectiveness analysis, 13 which could have a negative impact
on prescribing rates of drugs and drug therapies that are found less effective
than their alternatives.
Payor trends that affect drug prices include increased measures to control
utilization and reimbursement, such as cost-sharing, tiered formularies,
prior authorization, and utilization review. Consumers have been affected
by trends including increased unemployment causing workers to lose
employee health benefits and economic problems that prompt employers to
cut back coverage to retained employees. Out-of-pocket drug expenditures
increase as plans impose cost-sharing measures and higher numbers enter
12. FDA, Abbreviated New Drug Application (ANDA): Generics, http://www.fda.gov/
Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovaAppli
cations/AbbreviatedNewDrugApplicationANDAGenerics/default.htm (last visited Oct. 24,
2009) [hereinafter ANDA]; Matthew Avery, Note, Continuing Abuse of the Hatch- Waxman
Act by Pharmaceutical Patent Holders and the Failure of the 2003 Amendments, 60
HASTINGS L.J. 171, 176 (2008).
13. Comparative effectiveness research compares the relative effectiveness of various
medical treatments. See U.S. Dep't of Health & Human Servs., Comparative Effectiveness
Research Funding, http://www.hhs.gov/recovery/programs/cer/ (last visited Nov. 15 2009).
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the ranks of the unemployed and underemployed. Certain trends, however,
promote access. For example, the approaching patent cliff could increase
the availability of generics. Similarly, chain drug stores promote discounted
generics and some offer free antibiotics.
Part V discusses industry strategies that can affect pricing.
Pharmaceutical manufacturers are publicly-held corporations that employ
strategies to maximize profits and return on investment in order to benefit
their shareholders. As such, they have devised a number of strategies to
compete in the health care marketplace and to thwart competition by
generics manufacturers and other pharmaceutical innovators. These
strategies include product migration pricing, switching drugs to over-the-
counter status, and promotional activities such as direct-to-consumer
advertising to increase market share.
Part VI reviews a number of proposals to reform the pharmaceutical
component of the health care system. Proposed federal legislation would
amend the antitrust laws to discourage innovators and generics
manufacturers from negotiating "reverse payment" agreements whereby the
innovator pays the generics challenger and the generics company consents
not to enter the market until an agreed-upon date. Legislation has been put
forward to permit the development and marketing of generic biotechnology
products, as well as promotion of generics through consumer education
campaigns. Several proposals would allow importation of drugs from
countries whose direct or indirect price control strategies result in lower
prices. To make prescription drugs more affordable to Medicare
beneficiaries, a proposed reform would enable the Medicare prescription
drug program (Part D) to negotiate directly with pharmaceutical
manufacturers to obtain volume discounts. Prescription drug expenditures
could also be decreased by using the results of comparative-effectiveness
research and cost-benefit analysis to select drugs to treat patients more
effectively, efficiently, and economically. Proposed regulations on
promotional expenditures by pharmaceutical companies could impact
demand and market share, and reduce major drug company costs that
contribute to high prices. Several proposals address the compulsory
licensing or auctioning of pharmaceutical patents. Finally, access and
affordability are examined in light of proposals for universal coverage.
I. THE IMPORTANCE OF PRESCRIPTION MEDICATION
Pharmaceuticals and biologicals 14 are an indispensible part of modern
14. A pharmaceutical is a chemistry-based drug based on a small molecule. A biological
is a drug based on a protein manufactured from a living organism, such as a vaccine. See
Robert Pear, Congress Seeks Compromise to Approve Generic Biotechnology Drugs, N.Y.
TIMES, Apr. 8, 2007, § 1, at 22 [hereinafter Pear, Congress Seeks Compromise].
[Vol. 19
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health care. The history of pharmaceutical innovation describes a gradual
alleviation of human sickness and suffering that has resulted in a status of
health and longevity unimaginable a century ago. The discovery of a
method to isolate insulin in 1922 helped prevent diabetics from dying of
slow starvation.15 The "therapeutic revolution" of the 1940s, 16 which was
accelerated during World War II, protected millions against infection
through the synthesis of penicillin.' 7 New medicines decreased U.S. deaths
from HIV/AIDS from the 1995 rate of 16.2 per 100,000 to 4.9 deaths in
2002.18 Prescription drugs help prevent cancer recurrence 19 and can treat
and reduce the risk of heart disease, 20 accounting for 40 percent of the
increase in life expectancy.2'
One example of the importance of prescription medications is
antihypertensive medicines, which reduce deaths and hospitalizations.
Without such medications, an estimated 86,000 deaths and 833,000
hospitalizations would have occurred in the U.S. between 1999 and 2000.22
Treating hypertension with pharmaceuticals can result in an annual 38
percent decrease in the number of hospitalizations for stroke, and a 25
percent reduction in the number of hospitalizations for heart attack.23
Following treatment guidelines for hypertension could avoid 420,000
hospitalizations and 89,000 deaths.
24
Pharmaceuticals allow individuals to manage the symptoms of physical
and mental illnesses including epilepsy,25 depression,26 multiple sclerosis,
27
15. RICHARD A. EPSTEIN, OvERDOSE 6 (2006).
16. ALFRED D. CHANDLER, JR., SHAPING THE INDUSTRIAL CENTURY: THE REMARKABLE
STORY OF THE EVOLUTION OF THE MODERN CHEMICAL AND PHARMACEUTICAL INDUSTRIES
179 (2005).
17. EPSTEIN, supra note 15, at 3.
18. PHARM. RESEARCH & MFRS. OF AMERICA, VALUE OF MEDICINES: FACTS AND FIGURES
2006 11 (2006), http://www.phrma.org/files/Value%20oP/20Medicine%202006.pdf.
19. Id. at 12, 16.
20. Id. at 13.
21. Id. at 10.
22. Id. at 19.
23. PHARM. RESEARCH & MFRS. OF AMERICA, SHARP DECLINE IN PRESCRIPTION DRUG
SPENDING GROWTH 6 (2008), http://www.phrma.org/files/Drug%2OSpending / 20Brochure
%20FINAL.pdf [hereinafter SHARP DECLINE].
24. Id.
25. Epilepsy Found, Treatment, http://www.epilepsyfoundation.org/about/treatment/
(last visited Sept. 8, 2009).
26. Mayo Clinic, Depression (Major Depression): Treatments and Drugs,
http://www.mayoclinic.com/health/depression/DS00175/DSECTION=treatments-and-drugs
(last visited Sept. 8, 2009).
27. Mayo Clinic, Multiple Sclerosis: Treatments and Drugs, http://www.mayoclinic
.com/healthlmultiple-sclerosis/DSOO1 88/DSECTION--treatments-and-drugs (last visited
Sept. 8, 2009).
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obsessive compulsive disorder,28 and scores of other painful and debilitating
illnesses. Fifty-four percent of American adults report that they currently
take prescription drugs, and nineteen percent of adults say they take four or
more medicines each day.2 9 Sixty-four percent of U.S. households have a
member who regularly uses prescription drugs.3 °
II. ACCESS TO PRESCRIPTION PHARMACEUTICALS
Obtaining an outpatient prescription medication depends on a variety of
factors. A consumer must have access to a provider with prescribing
privileges and must be able to obtain any test necessary to determine the
need for or appropriateness of a given drug. He or she must have either
health coverage (along with the means to pay any premium, deductible, co-
insurance or co-pay) or funds to pay for the product out-of-pocket, as well
as the ability to travel to a retail pharmacy to purchase the product or to
obtain it from a mail-order pharmacy using either the postal system or the
Internet. Access also depends on the information available to the consumer
regarding diseases, treatment options, possible side effects,
contraindications, and pharmaceutical alternatives including the availability
of generics.
Physicians use the term "treatment gap" to refer to individuals who are
at-risk but do not receive therapy. For example, over sixty percent of those
at intermediate risk for a cardiovascular event do not receive treatment
either because they do not have physicians or because their physicians have
not offered treatment.31 Patients' failure to adhere to medication therapy
costs the United States an estimated $100-300 billion in lost productivity
and unnecessary health care spending every year.
32
Focusing on health insurance coverage and pharmaceutical pricing,
therefore, addresses only part of the access problem, albeit a significant
part: 79 percent of American adults believe drug prices are unreasonable,
and 41 percent report problems, with 16 percent reporting serious problems
28. Mayo Clinic, Obsessive-Compulsive Disorder (OCD): Treatments and Drugs,
http://www.mayoclinic.com/health/obsessive-compulsive-
disorder/DS00189/DSECTION=treatments-and-drugs (last visited Sept. 8, 2009).
29. KAISER FAMILY FOUND., KAISER PUBLIC OPINION SPOTLIGHT: VIEWS ON
PRESCRIPTION DRUGS AND THE PHARMACEUTICAL INDUSTRY 1 (2008), http://www.kff.org/
spotlight/rxdrugs/upload/Rx Drugs.pdf [hereinafter KAISER SPOTLIGHT].
30. Press Release, Pew Internet & Am. Life Project, One-Quarter of American Adults
Have Used the Internet to Find Prescription Drug Information (Oct. 10, 2004),
http://www.pewinternet.org/Press-Releases/2004/0nequarter-of-American-adults-have-used-
the-intemet-to-find-prescription-drug-information.aspx
31. Mary E. Tinetti, Over-the-Counter Sales of Statins and Other Drugs for
Asymptomatic Conditions, 358 NEW ENG. J. MED. 2728, 2728 (2008).
32. SHARP DECLINE, supra note 23, at 5.
[Vol. 19
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affording medication.33 According to the Kaiser Family Foundation:
Three in ten adults (29%) say they have not filled a prescription because
of the cost in the last two years, and nearly a quarter (23%) say they have
cut pills in half or skipped doses in order to make a medication last
longer.... Problems paying for prescription drugs are even more
common among those who take larger numbers of medications or are in
lower income brackets.
34
The Center for Studying Health System Change reports that:
After remaining steady in the early part of the decade, the proportion of
Americans under age 65 reporting problems affording prescription drugs
increased from 10.3 percent in 2003 to 13.9 percent in 2007-a 35
percent increase... Approximately 36.1 million working-age (19-64)
adults and children went without prescription drugs because of cost
concerns in 2007, an increase of 11.7 million people from 2003.35
Among working age adults, unmet drug needs increased from 13.8
percent in 2003 to 17.8 percent in 2007 (an increase of 29 percent).36
Among children, unmet need for prescription medication rose from 3.1
percent in 2003 to 5 percent in 2007 (children tend to require fewer
prescription drugs than adults).37 According to the Center for Studying
Health System Change, the increase is likely the result of higher prescribing
rates, increased drug prices, higher patient cost sharing under private health
plans, and market entry of expensive new pharmaceuticals.38
A March 2009 poll indicated that in 2008, 22 percent of American adults
did not fill a prescription because of cost, 17 percent took a medication less
frequently than directed, and 51 percent of the uninsured did not see a
physician when needed (compared to 24 percent among those with
insurance).39
The uninsured, individuals who lack private or governmental health
coverage, pay out-of-pocket for prescription medications as well as for the
physician visit to obtain a prescription. According to the U.S. Census
Bureau, 45.7 million Americans were uninsured in 2007.40 One study
33. KAISER SPOTLIGHT, supra note 29, at 12.
34. Id. at 12.
35. FELLAND & RESCHOVSKY, supra note 9, at 1.
36. Id.
37. Id.
38. Id.
39. HARRIS INTERACTIVE, MAJORITY OF U.S. ADULTS WORRIED ABOUT COST OF MEDICAL
CARE AND INSURANCE: MANY FAIL TO GET NECESSARY CARE DUE TO COST 1 (2009),
http://www.harrisinteraetive.com/news/pubs/harrishealthday.poll_2009-03-09pdf.
40. U.S. CENSUS BUREAU, INCOME, POVERTY, AND HEALTH INSURANCE COVERAGE IN THE
UNITED STATES: 2007 20 fig. 6 (2008), http://www.census.gov/prod/2008pubs/p60-235.pdf.
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estimates 86.7 million (one in three U.S. residents under the age of 65) went
without insurance at some point during 2007 and 2008.41 Individuals with
health insurance may be considered "underinsured" because their out-of-
pocket medical expenses are high relative to their income.42 According to
the Commonwealth Fund, 25 million insured adults were underinsured in
2007 (a 60 percent increase from the 16 million underinsured in 2003). 41
Underinsured adults are less likely to have prescription drug coverage and
are more likely to forego care. 4 An underinsured individual may lack
coverage for treatment of a pre-existing condition or may have difficulty
paying for treatment due to a high deductible. He or she may be required to
pay a portion of the retail prescription price due to cost sharing
requirements including co-pays and co-insurance. If a given prescription
medication is not covered under a health insurance policy, an insured
individual may be required to pay the entire cost out of pocket. This can
happen if the drug is not listed in the plan formulary or if the insurance
company declines coverage of a drug that it deems experimental.45
Medicare beneficiaries who decline to elect outpatient prescription drug
coverage under Part D4 6 and who lack supplemental sources of health
insurance may be underinsured. Similarly, Medicare beneficiaries who are
covered by a Part D prescription drug plan are often uninsured for
prescription drugs during the coverage gap commonly referred to as the
doughnut hole.47 Patients with private insurance paid for approximately
41. Analysis. 86.7M in U.S. Without Insurance, UNITED PRESS INT'L, March 14, 2009,
http://www.upi.com/TopNews/2009/03/04/Analysis-867M inUS without-insurance/UPI
-15511236186872/.
42. THE COMMONWEALTH FUND, INSURED BUT POORLY PROTECTED: How MANY ARE
UNDERINSURED? U.S. ADULTS TRENDS, 2003 TO 2007 2 (2008),
http://www.commonwealthftmd.org/-/media/Files/Publications/In / 20the%20Literature/200
8/Jun/How% 20Many% 2OAre% 20Underinsured% 200 20Trends% 20Among% 20U% 20S% 20
%20Adults%20%202003%20and%202007/Schoen-howmanyareunderinsured chartpack0%62
Opdf.pdf.
43. Id.
44. Cathy Schoen et al., Insured But Not Protected: How Many Adults Underinsured?,
HEALTH AFF. W5-289, 295, 297 (2005), http://content.healthaffairs.org/cgi/reprint/
hlthaff.w5.289vl ?maxtoshow=&HITS=10&hits=l 0&RESULTFORMAT=&title=Insured+b
ut+not+protected&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&s
earchid = 1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT.
45. Vanessa Fuhrmans, A Family Illness, and Fewer Friends Who Can Help, WALL ST.
J., Mar. 5, 2009, at A14.
46. Pursuant to the Medicare Prescription Drug, Improvement, and Modernization Act
of 2003, Medicare beneficiaries could enroll in outpatient prescription drug coverage under
Medicare starting on Jan. 1, 2006. See Medicare Prescription Drug, Improvement, and
Modernization Act of 2003, P.L. No. 108-173, 117 Stat. 2066 (2003).
47. DEP'T. OF HEALTH & HUMAN SERVS., How THE COVERAGE GAP WORKS IN MEDICARE
DRUG PLANS 1 (2008), http://www.cms.hhs.gov/partnerships/downlads/1 1240-P.pdf. When
a Part D beneficiary and his or her plan has spent $2,700 (2009) for covered drugs, the
beneficiary is in the coverage gap or "doughnut hole" and must pay 100% of the cost of their
8
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one-third of their prescription drug costs out-of-pocket in 2004.48
Rising health care costs and the current economic crisis affect the health
care choices and behavior of insured individuals and the coverage decisions
of health plans and employers. For the first time in more than a decade, the
number of prescriptions dispensed in the United States decreased in the first
eight months of 2007, an indication that people may be skimping on
prescription drugs to save money. 49 The research firm IMS Health reported
that the decline occurred in June, July, and August, suggesting a link with
the time period when Medicare Part D beneficiaries tend to enter the
doughnut hole.50 According to a survey by the employee benefits
management firm Watson Wyatt Worldwide, 17 percent of the 2,487
surveyed employees at large U.S. companies either did not fill a
prescription or skipped doses of prescribed medicine in 2008, an increase
from 13 percent in 2007.51 But the news is not all bad: more employees
chose a lower-cost drug option (46 percent, compared to 42 percent in
2007) and more spoke with their doctors about seeking more affordable
medical treatments (14 percent, compared to 9 percent in 2007). An
increased number of the surveyed employees made efforts to improve their
personal care (66 percent as compared to 61 percent in 2007).52
Employee health coverage has grown increasingly expensive: employers
have raised premiums 53 and the trend in health insurance plans is to require
higher deductibles, greater cost sharing, and to restrict the scope of benefits
which shifts more of the financial risk to employees.54 According to
benefits firm Hewitt Associates, out of 340 large firms employing a total of
more than 5 million workers, two out of three employers seek to reduce
health-care subsidies in 2010, which will likely increase employees' out-of-
pocket costs. 55 Employers are also considering mandating generic drug use
and requiring employees to purchase maintenance drugs from mail-order
prescriptions, in addition to their Part D plan premiums, until he or she has paid the $4,350
(2009) out-of-pocket drug costs that qualify him or her for catastrophic coverage.
48. SHARP DECLINE, supra note 23, at 4.
49. Stephanie Saul, In Sour Economy, Some Scale Back on Medications, N.Y. TIMEs,
Oct. 22, 2008, at Al. The article mentions that patients may be splitting pills or taking them
less often rather than foregoing medication altogether or declining to purchase medication
for symptomless conditions such as statins for cholesterol. The cause of the downturn may
also be due to safety concerns about certain pharmaceuticals.
50. Id.
51. Press Release, Watson Wyatt Worldwide, U.S. Workers Taking Steps To Lower
Medical Costs, Watson Wyatt Survey Finds (Dec. 10, 2008), http://www.watsonwyatt.com/
us/news/press.asp?ID=20212.
52. Id.
53. Furhmans, supra note 45, at A14.
54. Schoen et al., supra note 44, at W5-289.
55. Bruce Japsen, Employers to Shrink Insurance Benefits, CHI. TRE3., Mar. 5, 2009,
News, at 20.
9
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pharmacies. 6 Four percent of employers studied are taking steps to
discontinue providing health benefits altogether. In 2009, workers are
expected to average out-of-pocket monthly health care costs of $156 (a 10. 1
percent increase from 2008).8
It is estimated that 75 million Americans were either underinsured or
uninsured in 2007 (an estimated 42 percent of all adults, compared to 35
percent in 2003), 59 and every member of that population is vulnerable to the
potential inability to afford a required prescription medication.
The Institute of Medicine recently released a study entitled "America's
Uninsured Crisis: Consequences for Health and Health Care" that states,
"for children with special health care needs, being uninsured can have
disastrous consequences" 60 and provides the following example:
Ginny was born with a congenital cardiac anomaly that was repaired
successfully when she was 5 years old and funded through her Medicaid
insurance. She had steadily followed up with her pediatric cardiologists,
and, as soon as she developed an arrhythmia at 11 years old, it was
discovered and her regimen of anti-arrhythmic medication was titrated to
perfectly control her heart's rhythm.
As the end of her Medicaid eligibility approached, Ginny scoured her
small town for jobs, but none of the small businesses there would hire
her. At the time of her 19th birthday, Ginny's Medicaid drug coverage
stopped, and she was left without the means to buy her anti-arrhythmic
medications and went without. Ginny died of a fatal arrhythmia 5 months
later.61
The Cox family in North Carolina has health insurance but coverage
gaps (sometimes totaling $40,000 per year) require that they rely on family
members, friends, and their church to help them afford medical treatment
for their three children who have Schwachmann Diamond Syndrome.62
Economic difficulties made donations shrink and the family is making a
56. Id.
57. Id.
58. Id.
59. SARA R. COLLINS ET AL., THE COMMONWEALTH FUND, LOSING GROUND: How THE
Loss OF ADEQUATE HEALTH INSURANCE is BURDENING WORKING FAMILIES 8 (2008),
http://www.commonwealthfund.org/-/media/Files/Publications/Fund%/ 20Report/2008/Aug/
Losing%20Ground%20%2OHow%20the%2OLoss%20ofo20Adequate%2OHealth%20Insura
nce%20Is%20Burdening%20Working%2OFamilies%20%208212%20Finding/Collins losin
ggroundbiennialsurvey2007_1163%20pdf.pdf.
60. INST. OF MED. OF THE NAT'L ACADS., AMERICA'S UNINSURED CRISIS: CONSEQUENCES
FOR HEALTH AND HEALTH CARE 63 (2009), http://books.nap.edu/openbook.php?
record id=1251 1&page 13.pdf [hereinafter UNINSURED CRISIS].
61. Id.
62. Fuhrmans, supra note 45, at A14.
[Vol. 19
10
Annals of Health Law, Vol. 19 [2010], Iss. 2, Art. 4
http://lawecommons.luc.edu/annals/vol19/iss2/4
2010] Pharmaceutical Pricing: Review of Access Proposals 321
contingency plan to move into their vacant trailer and live on relatives'
property in order to afford their children's treatment.
63
The elderly, disabled, and adults with chronic health problems are
significantly more likely to skimp on medication because of cost:
When faced with high out-of-pocket costs for prescription drugs, many
patients, particularly the elderly and disabled, skip or take smaller doses
of their medications, or stop filling prescriptions... As many as 29
percent of disabled Medicare beneficiaries and 13 percent of elderly
Medicare beneficiaries have reported such cost-related underuse, and the
rates are even higher among individuals with low incomes and/or
multiple chronic conditions... Nonadherence to medication therapy has
been shown to lead to negative health outcomes, and greater use of
emergency department and inpatient hospital services.
64
More than 60 percent of the uninsured chronically ill, and 46 percent of
the underinsured chronically ill, report skipping medication due to cost
(compared with 15 percent of the chronically ill with adequate health
insurance).65 If the co-payment doubles for a prescription medication
prescribed for a chronic condition, adherence is reduced by 25 to 45
percent, hospitalizations increase by 10 percent, and visits to the emergency
room increase by 17 percent.66
The Institute of Medicine (IOM) reports that qualifying for Medicare
coverage can significantly improve the cardiovascular health status of
previously uninsured adults, 67 although it is unclear whether the
improvement is due to prescription drugs or another form of medical
treatment. Another study discussed by the IOM involved two groups of
diabetic adults.68 The glycemic control in the uninsured group was
significantly worse than that of the group covered by Medicare. 69 However,
after age sixty-five both groups had similar outcomes. 70 The 1OM report
states that Medicare coverage improves the health of uninsured adults with
chronic disease in several ways, but that "[a]ccess to prescription drugs
appears to be especially important previously uninsured adults who
gained prescription drug coverage experienced the greatest health
63. Id.
64. Julie M. Donohue et al., Potential Savings from an Evidence-Based Consumer-
Oriented Public Education Campaign on Prescription Drugs, 43 HEALTH SERVICES
RESOURCES 1558, 1558 (2008).
65. COLLINS ET AL., supra note 59, at x.
66. SHARP DECLINE, supra note 23, at 5.
67. UNINSURED CRISIS, supra note 60, at 8.
68. Id. at 77.
69. Id.
70. Id.
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improvement." 71
Prescription drug prices can lead to non-adherence among the poor:
Prescription drug prices are a significant barrier to appropriate
medication use. Cost-related underuse in the uninsured is common, and
even small increases in drug prices can dramatically affect medication
adherence among the poor... There are clear adverse health effects
associated with decreased medication adherence, including poorer control
of chronic disease and higher rates of hospitalization and emergency
room visits...
While many low-income individuals obtain prescription coverage
through government programs and may receive relatively generous drug
benefits, those who have no prescription coverage are required to pay the
full retail price charged at their pharmacies. More than half of uninsured
adults younger than 65 come from low-income families... Because of
discounts negotiated by insurance companies, cash-paying customers are
charged higher prices for their drugs than their insured counterparts...
72
Approximately 75 million uninsured and underinsured 73 risk inability to
access needed prescription medications.74 The risk is greatest for the
chronically ill who require maintenance medication. Inability to acquire
pharmaceuticals can result in a worsening of symptoms or failure to
improve, which can cause preventable pain and premature death as well as
economic consequences to the individual, his or her family, and society as a
whole.
The structure and dynamics of the pharmaceutical industry directly
impacts the availability and pricing of prescription drugs, as well as the
nature and feasibility of efforts to make drugs more accessible through
reform. An individual's access to pharmaceuticals depends on the
pharmaceutical industry that develops, obtains approvals, manufactures,
markets, and sells prescription medications.
III. THE PHARMACEUTICAL INDUSTRY
The pharmaceutical industry grew out of the chemical industries of
Germany and the United States in the late nineteenth century.75 A buyer in
1885 could purchase medicinal preparations from manufacturers whose
names are familiar today: Merck, SmithKline, Eli Lilly, and John Wyeth,
71. Id.
72. Walid F. Gellad et al., Variation in Drug Prices at Pharmacies: Are Prices Higher
in Poor Areas?, 44 HEALTH SERVICES RESOURCES 606, 606-07 (2009).
73. COLLINS ET AL., supra note 59.
74. See text accompanying notes 40-48.
75. CHANDLER, supra note 16, at 178-79.
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among others.76
Traditional "innovator" pharmaceutical manufacturers research, develop,
and patent a drug, obtain approval that the drug is safe and effective from
the Food and Drug Administration,7 7 market and promote the drug,78 and
are entitled to charge monopoly profits and exclude competition for the
duration of the patent.79 Generics manufacturers produce drugs that are the
therapeutic equivalents of drugs developed by innovators 8 and market them
at a lower cost.81
Traditionally, drug wholesalers purchased pharmaceuticals at a discount
from manufacturers and sold them to retail and institutional pharmacies.82
Today, a more complicated supply chain includes a variety of public and
private payors and negotiators, including: private and employee-sponsored
health plans, government programs such as Medicare and the U.S.
Department of Veterans Affairs (the "VA"), pharmacy benefits managers,
and prescription assistance organizations.83 The industry structure and
stakeholders create the basis for pharmaceutical pricing dynamics, which
ultimately affects consumer access and the affordability of prescription
medications.
A. Innovator Pharmaceutical Manufacturers
Pharmaceutical innovators are manufacturers that research and develop
new products, obtain FDA approval through testing and clinical trials,
secure patent protection, and promote a "brand-name" product to
physicians, pharmacists, and consumers. 84 Patent protection allows
76. Id. at 177.
77. See generally PHARM. RESEARCH & MFRS. OF AM., DELIVERING ON THE PROMISE OF
PHARMACEUTICAL INNOVATION: THE NEED TO MAINTAIN STRONG AND PREDICTABLE
INTELLECTUAL PROPERTY RIGHTS (2002), http://www.ftc.gov/os/comments/
intelpropertycomments/phrma020422.pdf.
78. See generally MEREDITH B. ROSENTHAL ET AL., KAISER FAMILY FOUND., DEMAND
EFFECTS OF RECENT CHANGES IN PRESCRIPTION DRUG PROMOTION (2003),
http://www.kff.org/rxdrugs/upload/Demand-Effects-of-Recent-Changes-in-Prescription-
Drug-Promotion-Report.pdf.
79. EPSTEIN, supra note 15, at 9.
80. FDA, Drugs@FDA Glossary of Terms, http://www.fda.gov/Drugs/
InformationOnDrugs/ucm079436.htm (last visited Oct. 6, 2009).
81. Generic Pharmaceutical Assoc., About Generics, http://www.gphaonline.org/about-
gpha/about-generics (last visited Oct. 6, 2009).
82. KAISER FAMILY FOUND., FOLLOW THE PILL: UNDERSTANDING THE U.S. COMMERCIAL
PHARMACEUTICAL SUPPLY CHAIN 1 (2005), http://www.kff.org/rxdrugs/upload/Follow-The-
Pill-Understanding-the-U-S-Commercial-Pharmaceutical-Supply-Chain-Report.pdf.
83. See generally id.
84. See Michelle Meadows, FDA, New FDA Initiatives to Improve Drug Reviews and
Reduce Legal Loopholes, http://www.fda.gov/Drugs/EmergencyPreparedness/
BioterrorismandDrugPreparedness/ucm134448.htm (last visited Oct. 24, 2009); FDA, The
Impact of Direct-to-Consumer Advertising, http://www.fda.gov/Drugs/ResourcesForYou/
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innovators to demand monopoly prices for the life of the patent.8 5
Higher drug prices fund research and the development (R&D) of new
drugs, but public policy may have to choose between the development of
new drugs and lower prices that increase access to drugs.86 There is
evidence that R&D spending increases with drug prices.87 Innovator
pharmaceutical manufacturers attempt to develop "blockbuster" drugs with
annual sales of at least $1 billion in order to offset the high cost of R&D
and to fund the development of subsequent products.88
The Food, Drug and Cosmetic Act requires an innovator pharmaceutical
manufacturer to submit a New Drug Application (NDA) and prove the
product safe and effective before marketing it to the public. 89 Researching
and developing a new prescription medication can take ten to fifteen years
and the efforts of thousands of researchers and regulators. 90 Average R&D
costs for a single drug can exceed $1 billion.91 Millions of dollars are spent
on potential drugs that fail in clinical trials.92 It is estimated that only one
out of 5,000 to 10,000 potential new pharmaceuticals makes it to human
trials,93 and many drugs that succeed in animal trials fail when tested on
humans.
94
By contrast, generic drugs sell for much lower prices than brand-name
equivalents.95 Generics avoid the cost of R&D and the expenses associated
with NDA approval from the FDA.96
Consumers/ucm143562.htm (last visited Oct. 24, 2009).
85. EPSTEIN, supra note 15, at 9.
86. Alan M. Garber & Victor Fuchs, Brookings Institution, Medical Innovation:
Promises and Pitfalls, http://www.brookings.edu/articles/2003/winter-technology fuchs.
aspx (last visited Oct. 24, 2009).
87. Carmelo Giaccotto et al., Drug Prices and Research and Development Investment
Behavior in the Pharmaceutical Industry, 48 J.L. & EcON. 195, 212 (2005) (suggesting that
an increase of ten percent in the growth of real drug prices is linked to an increase of almost
six percent in R&D intensity).
88. Field, supra note 3, at 258.
89. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355 (2006).
90. Billy Tauzin, The Next 50 Years of Medical Innovation Has Already Started (Nov.
1, 2008), http://www.phrma.org/aboutphrma/straighttalk-from-billytauzin/the next 50
years of medical innovatin has alreadystarted/.
91. Id.
92. Gregory A Petsko, Pharmacogenomics Arrives, 5 GENoME BIOLOGY 108, 108
(2004).
93. Barbara Martinez & Jacob Goldstein, Big Pharma Faces Grim Prognosis, WALL ST.
J., Dec. 6, 2007, at Al.
94. Id.
95. ANDA, supra note 12.
96. Id.
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B. Generics Manufacturers
Generics manufacturers duplicate the active ingredient in a brand-name
pharmaceutical and are free to market the generic drug if it does not
infringe on the brand name drug's patent, or when the brand-name drug's
patent has expired.97 On average, generics cost 30 to 80 percent less than
their brand-name equivalents.98
States, health plans, and employers often require pharmacists to fill
prescriptions with a generic, if available. In 2008, 63.7 percent of U.S.
prescriptions were filled by generics,99 a slight decrease from 67 percent in
1997 but higher than the 2006 and 2005 figures of 63 and 60 percent,
respectively. 100  According to IMS, U.S. retail sales of generic
pharmaceuticals totaled approximately $33 billion in 2008.101
The FDA requires that a generic contain the same active ingredient as the
brand-name drug, although its colorants, binders, and fillers may differ.
10 2
The generic must deliver 80 to 125 percent of the amount of active
ingredient in the brand-name drug, but the Generic Pharmaceutical
Association states that on average, a generic does not vary significantly
from the corresponding brand-name drug. 10 3 In 1997, researchers found an
average of less than 4 percent difference in blood levels between generics
and originals.
10 4
In spite of the close resemblance between generics and their brand-name
counterparts, there have been incidents of patients claiming generics lack
the original's efficacy, most notably with epilepsy drugs. Patient advocacy
groups, including the Epilepsy Foundation of America, encourage states to
prohibit "drug product substitution," a process by which a pharmacist can
substitute a generic for a brand name drug without permission from the
prescribing physician.0 5
Many states promote the use of generic drugs through drug product
substitution laws that allow a pharmacist to fill a prescription with a generic
97. Avery, supra note 12.
98. Micah Hartman et al., National Health Spending in 2007: Slower Drug Spending
Contributes to Lowest Rate of Overall Growth Since 1998, 28 HEALTH AFF. 246, 250 (2009).
99. Intercont'l Marketing Servs., IMS Health Reports Annual Global Generics
Prescription Sales Growth of 3.6 Percent, to $78 Billion, http://www.imshealth.com/
portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f61101941 8c22a/?vgnextoid=2943d52
288dle1 10VgnVCM100000ed152ca2RCRD&vgnextfmt=default (last visited Oct. 6, 2009).
100. Hartman et al., supra note 98, at 250.
101. Intercont'l Marketing Servs., supra note 99.
102. Shannon Pettypiece, Seizure Threat Tied to Drug-Swap Laws May Hurt Teva,
Mylan, BLOOMBERG, Feb. 11, 2009, http://www.bloomberg.eom/apps/news?pid=20601103&
sid-a9k3iDl4bTHo&refel-us.
103. Id.
104. Id.
105. Id.
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if the prescribing physician does not specifically disallow generic
substitution. 10 6 Thirty states mandate substitution if a generic is available.
10 7
However, several states, including North Carolina, Tennessee, Utah, and
Hawaii, have passed measures that stop drug product substitution,
according to the Generic Pharmaceutical Association.'08 Druggists in those
states must now obtain patient or doctor consent, or sometimes both, for
switches involving certain classes of medicine. 109
Congress promoted generics pharmaceutical marketing with the passage
of the Drug Competition and Patent Term Restoration Act of 1984,
commonly referred to at the Hatch-Waxman Act.110 The Hatch-Waxman
Act allows a generics manufacturer to submit to the FDA an Abbreviated
New Drug Application (ANDA), which is a less expensive approval process
than the NDA process and does not require clinical trials.'11 As a result,
between 1984 and mid-2007, the use of generic drugs in the U.S. increased
from nineteen to sixty-seven percent of all prescriptions. 1
12
Blurring the distinction between innovator pharmaceutical manufacturers
and generics manufacturers, some innovators have entered the generics
industry. Novartis, an innovator, owns Sandoz, a generics manufacturer,
11 3
and Pfizer manufactures generics through its Greenstone unit.1 14 Other
innovators negotiate arrangements with independent generics manufacturers
under which the generics concern is licensed to sell "authorized generics"
that are identical to the original brand-name drug. 1 5 Authorized generics
can also refer to a generics version of a brand-name drug that is
manufactured and sold by the innovator drug company that sells the brand-
name equivalent (or by a division of that company). 1 6
A number of large chain pharmacies and discount stores, including Wal-
106. Richard Cauchi, Substituting Drugs: State Roles, LEGISBRIEF (Nat'l Conf. of St.
Legislatures, Denver, Colo.), June-July 2009.
107. Evan H. Langdon, Comment, Switching to Generic: The Need for Physician and
Patient Consent When Substituting Antiepileptic Medication, 25 J. CONTEMP. HEALTH L. &
POL'Y 166, 179 (2008).
108. Pettypiece, supra note 102.
109. Id.
110. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-
417, 98 Stat. 1585 (1984) (codified as amended 21 U.S.C. § 355 etseq. (1994)).
111. Stephanie Greene, A Prescription for Change: How the Medicare Act Revises
Hatch- Waxman to Speed Market Entry of Generic Drugs, 30 J. CORP. L. 309, 309 (2005).
112. SHARP DECLINE, supra note 23.
113. Heather Timmons & Tom Wright, Novartis to Buy Two Makers of Generics, N.Y.
TIMEs, Feb. 22, 2005, at Cl.
114. Pfizer, Established Products Fact Sheet, http://www.pfizer.com/news/press-kits/
establishedproducts fact sheet.jsp (last visited Oct. 18, 2009).
115. Martinez & Goldstein, supra note 93.
116. FTC, AUTHORIZED GENERICS: AN INTERIM REPORT (2009), http://www.ftc.gov/
os/2009/06/P062105authorizedgenericsreport.pdf.
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Mart, CVS Caremark, Walgreen Co., and Rite Aid Corp., have
implemented aggressive drug discount programs that enable consumers to
purchase certain generic drugs at prices that can be as low as $4 for a one-
month supply.11 7 Wal-Mart announced that its program saved its customers
over $610 million in its first year." 8 Several pharmacies offer free
antibiotics as well, including Meijer, ShopRite, Giant Food Stores, Stop &
Shop, and Wegmans.1 9 Some of these pharmacies have been criticized for
refusing to extend the discount prices to Medicaid and Medicare
beneficiaries, including those who have entered the doughnut hole and must
pay the full prescription drug cost out-of-pocket until they reach the
catastrophic coverage threshold.
120
Low-income individuals may not have full access to these programs
because chain pharmacies tend not to be located in low income areas, which
are more likely to be served by independent pharmacies with higher
prices.121 A recent study concluded that mean prices on pharmaceuticals are
sometimes highest in the poorest zip codes, thereby putting at a
disadvantage those who lack transportation to purchase medication at chain
stores. 122
There is a risk that these discount programs may be challenged under
laws prohibiting unfair trade practices and predatory pricing. 23 Predatory
pricing laws were originally enacted in various states to protect small
retailers from large retail chains. A legal challenge based on predatory
pricing laws could argue that large chain pharmacies could use discount
programs to drive competitors out of business then recoup their losses by
raising prices. 124 Discount programs have excluded certain drugs in
individual states due to state laws prohibiting retailers from selling items
below cost.
125
C. Biotechnology Manufacturers
Whereas traditional pharmaceutical manufacturers develop new drugs
117. Dinah Wisenberg Brin, Corporate News: Pharmacies Fight Touch Battle on
Generic Prices, WALL ST. J., Dec. 22, 2008, at B3.
118. NAT'L CONFERENCE OF STATE LEGISLATURES, GENERIC DRUG PRICING AND STATES,
2009 EDITION, http://www.ncsl.org/programs/health/generic$.htm.
119. Tara Parker-Pope, U.S. Warns of Danger in Giveaways of Antibiotics, N.Y. TIMES,
Mar. 5, 2009, at A22.
120. David Shaffer, Whistleblower: 'Low-Cost' Generic Drugs Not Cheap For All -
Walgreens and Some Other Pharmacies Charge More If the Government Is Buying, MINN.
STAR TRn3., Mar. 26, 2009, at IA.
121. Gellad et al., supra note 72, at 6.
122. Id. at 4.
123. NAT'L CONFERENCE OF STATE LEGISLATURES, supra note 118.
124. Id.
125. Id.
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using chemistry, biotechnology pharmaceutical companies use biological
processes to develop new drugs from living organisms. 126 Biotechnology
drugs include vaccines, treatments for cancer, diabetes, and cardiovascular
illness. 127 Although biotechnology is a relatively new addition to the
pharmaceutical industry, biotechnology companies that are members of the
Biotechnology Industry Organization (BIO) have thus far brought 254 new
drugs to market. 1
28
Ernst & Young estimates the American market for biotechnology drugs
exceeds $60 billion annually; 129 the generics drug industry expects that
figure to exceed $100 billion in 2011.130 Some biotech drugs are highly
profitable. For example, Genentech Inc. charges $4,400 per month for
Avastin, a cancer drug. 131 Patients with Gaucher disease sometimes pay
$200,000 for treatment with Cerezyme, a biotechnology drug from
Genzyme. 132 However, the biotechnology industry as a whole is risky
because many biotech companies fail to achieve profitability after investing
millions of dollars in research. 133 The United States has no process for the
approval of generic biological drugs.
D. Purchasers and Payors
1. Private Health Plans
In 2007, 202 million Americans were covered by private health
insurance.'1 34 Although most Americans with private health insurance obtain
their coverage through an employer, the number of employees covered by
employer-sponsored insurance is decreasing. 135 In 2005, sixty-four percent
126. Andrew Pollack, Costly Drugs Known as Biologics Prompt Exclusivity Debate,
N.Y. TIMES, July 22, 2009, at B1.
127. BIOTECHNOLOGY INDUS. ORG., HEALTH BROCHURE 1 (2009), http://bio.org/
aboutbio/HealthBrochure_2009.pdf.
128. Biotechnology Indus. Org., BIO Health Overview, http://bio.org/healthcare/ (last
visited Oct. 18, 2009).
129. Catherine Larkin, Waxman Limits Protections for Amgen, Genentech Drugs
(Update1), BLOOMBERG, March 11, 2009, http://www.bloomberg.com/apps/news?pid=
20670001 &refer=&sid=aG3mcgOKpd4E.
130. Alicia Mundy, Corporate News: Firms Prepare for a Fight Over Generic Drugs,
WALL ST. J., Mar. 12, 2009, at B4.
131. Martinez & Goldstein, supra note 93.
132. Larkin, supra note 129.
133. Andrew Pollack, For Biotech, A Tax Break Spells Hope, N.Y. TIMES, Dec. 10,
2008, at BI; see also Andrew Pollack, Drug Investors Lose Patience, N.Y. TIMES, Mar. 9,
2009, at BI.
134. U.S. Census Bureau, Health Insurance Coverage: 2007 - Highlights, http://
www.census.gov/hhes/www/hlthins/hlthin07/hlth07asc.html (last visited Oct. 18, 2009).
135. See PETER CUNNINGHAM ET AL., KAISER FAM. FOUND., THE FRAYING LINK BETWEEN
WORK AND HEALTH INSURANCE: TRENDS IN EMPLOYER-SPONSORED INSURANCE FOR
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of U.S. workers had access to outpatient prescription drug coverage through
an employer-provided health care plan, and fewer than fifty percent
participated in the prescription drug coverage. 
136
Private health plans employ a number of techniques to control the cost of
outpatient pharmaceuticals. Cost sharing, in the form of co-pays or co-
insurance, is the most familiar to consumers. A co-pay is a flat payment per
prescription or refill.137 Co-insurance requires the consumer to pay a
percentage of the cost of the drug.' 38 A health plan with a tiered formulary
frequently assigns graduated cost sharing to the various tiers to encourage
selection of generics and other lower cost drugs.139
Four-tier formularies started with Medicare drug plans (86 percent of
plans had Tier 4 in 2008)140 and have spread quickly to the private
insurance market. By 2008, 10 percent of private and employer sponsored
plans had Tier 4.141 Unlike a co-pay, which requires consumers to pay a flat
amount per prescription, Tier 4 designation requires a payment of 20 to 33
percent of the drug's cost, which can be burdensome because the monthly
cost of certain drugs can be in the thousands of dollars.
142
In the 1990s, it was not uncommon for consumers to expect to make a
small co-payment for any kind of medicine. 143 Today, incentive-based
formularies commonly assign co-payment amounts depending on the drug
prescribed, the price differential between a brand-name drug and lower cost
substitutes, and the various agreements negotiated among the insurer, the
manufacturer, and the pharmacy.1 44 In some cases, consumers are required
to pay up to one-half the price of a drug. 1
45
Other cost containment strategies commonly used by health plans
EMPLOYEES, 2000-2007 (2008), http://www.kff.org/uninsured/upload/7840.pdf.
136. PAUL A. WELCHER, BUREAU OF LAB. STATISTICS, ACCESS TO AND PARTICIPATION IN
EMPLOYER-PRoVIDED HEALTH CARE PLANS, PRIVATE INDUSTRY, 2005 (2006),
http://www.bls.gov/opub/cwc/cm2006012Och01.htm.
137. JOHN P. SOMMERS & BETH LEVIN CRIMMEL, MED. EXPENDITURE PANEL SURV.,
STATISTICAL BRIEF #209, CO-PAYS, DEDUCTIBLES, AND COINSURANCE PERCENTAGES FOR
EMPLOYER-SPONSORED HEALTH INSURANCE IN THE PRIVATE SECTOR, BY FIRM SIZE
CLASSIFICATION, 2006 2 (2008), http://meps.ahrq.gov/mepsweb/data-files/ublications/
st209/stat209.pdf.
138. Id.
139. Lesley Alderman, Strategies for Saving on Prescription Drugs, N.Y. TIMES, Feb 6,
2009, http://www.nytimes.com/2009/02/07/health/06patient.html.
140. Gina Kolata, Co-Payments Go Way Up For Drugs with High Prices, N.Y. TIMES
Apr. 14, 2008, at Al.
141. Id.
142. Id.
143. Cindy Parks Thomas, Incentive-Based Fornularies, 349 NEW ENG. J. MED. 2186,
2186 (2003).
144. Id.
145. Id.
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include: formularies that exclude certain drugs from coverage, dispensing
limits, caps on the quantity of drugs covered, utilization review, prior
authorization, step therapy, 146 mandatory generic substitution, reference
pricing, education strategies for consumers and physicians, 147 restrictions on
the pharmacy network, mail-order incentives, and disease management. 1
48
2. Government Programs
a. Medicare
Medicare is a government health insurance program for individuals age
sixty-five or older, certain disabled persons, and those with kidney failure
who require dialysis (End-Stage Renal Disease, or ESRD). 149 Medicare Part
A reimburses certain costs for hospital inpatients, skilled nursing facilities,
hospice, and some home health care. 5° Medicare originally reimbursed
hospitals on a cost-based system, but hospital costs rose dramatically under
this payment system. 151 Between 1965 and 1983, hospital costs increased
from $3 billion to $37 billion per year.152 Today, Part A pays most hospitals
a flat rate per case to reward hospitals for efficiency. 153 Medicare Part A
therefore covers, but does not separately reimburse for, prescription drugs
administered to Medicare beneficiaries as inpatients. Part A influences
pricing only indirectly by giving hospitals additional incentive to acquire
pharmaceuticals at the greatest possible discount.
By contrast, Medicare Part B influences pharmaceutical pricing directly,
but only with respect to a limited number of pharmaceutical products. Part
B reimburses outpatient physician fees for certain beneficiaries and covers a
146. Step therapy, also referred to as step protocol, requires a prescriber to begin
treatment with the most cost-effective, safest available drug. More expensive or risky drugs
are made available only to those patients who do not respond well to the earlier treatment.
Medterms Online Med. Dictionary, Definition of Step Therapy, http://www.medterms.com/
script/main/art.asp?articlekey=40302 (last visited Oct. 18, 2009).
147. JACK HOADLEY, KAISER FAM. FOUND., COST CONTAINMENT STRATEGIES FOR
PRESCRIPTION DRUGS: ASSESSING THE EVIDENCE IN THE LITERATURE 32, 72 (2005),
http://www.kff.org/rxdrugs/upload/Cost-Containment-Strategies-for-Precription-Drugs-
Assessing-The-Evidence-in-the-Literature-Report.pdf.
148. Thomas, supra note 143, at 2188.
149. Ctr. for Medicare & Medicaid Servs., Medicare Program - General Information,
http://www.cms.hhs.gov/MedicareGenInfo/ (last visited Oct 18, 2009).
150. Ctr. for Medicare & Medicaid Servs., Medicare Part A - General Information,
http://www.cms.hhs.gov/MedicareGenlnfo/02_Part%20A.asp (last visited Oct 18, 2009).
151. OFFICE OF EVALUATION AND INSPECTIONS, REGION IX, OFFICE OF THE INSPECTOR
GEN., OEI-09-00-00200, MEDICARE HOSPITAL PROSPECTIVE PAYMENT SYSTEM How DRG
RATES ARE CALCULATED AND UPDATED 1 (2001), http://oig.hhs.gov/oei/reports/oei-09-00-
00200.pdf.
152. Id.
153. Id.
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limited number of drugs that tend to be administered in a physician's
office. 154 Prior to 2004, Part B reimbursed prescription drugs at either the
amount billed by the physician or ninety-five percent of the Average
Wholesale Price (AWP), whichever was lower.155 The AWP is the
pharmacy industry's "sticker price," published by pharmaceutical
manufacturers in national price compendia (it is not an actual average of
prices paid by wholesalers). The prices reimbursed under Part B were
higher than the prices charged to physicians by their suppliers and the
Medicare program was overpaying millions of dollars annually under this
system. 156
The Medicare Prescription Drug, Improvement, and Modernization Act
of 2003 (MMA) 157 reformed Part B prescription drug reimbursement by
reimbursing most Part B drugs at 85 percent of AWP in 2004.158 In 2005
Part B began reimbursing drugs at 106 percent of the Average Sale Price
(ASP), a pricing benchmark that is defined by statute and based on reports
of actual transactions. 159  The reform substantially lowered the
reimbursement cost of many drugs.
160
Medicare Advantage (Part C) 16 1 and the Medicare Prescription Drug
Program (Part D) 162 offer beneficiaries a managed care benefit and an
outpatient prescription drug plan, respectively. Medicare Advantage plans
can include prescription drug coverage. 63 Both programs utilize private
insurance plans that submit benefit proposals for approval by CMS. CMS
does not negotiate prescription drug prices with the plans and therefore does
not directly influence pricing levels offered to beneficiaries. Instead, CMS
attempts to foster competition among plans by providing beneficiaries with
154. MEDICARE BENEFIT POLICY MANUAL, Chap. 15 Sec. 50 (Rev. 109 2009).
155. Hearing on Medicare Reimbursement of Physician-Administered Drugs Before the
Subcomm. on Health of the H. Comm. on Ways & Means, 109th Cong. 1 (2006) (statement
of Robert A. Vito, Regional Inspector General for Evaluation and Inspections, Office of
Inspector General., U.S. Department of Health and Human Services), available at
http://oig.hhs.gov/testimony/docs/2006/60713fm.pdf [hereinafter Hearing on Medicare
Reimbursement].
156. Id.
157. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L.
108-173, 117 Stat. 2006.
158. Hearing on Medicare Reimbursement, supra note 155.
159. Id. at 1-2.
160. Id. at2.
161. Balanced Budget Act of 1997, Pub. L. 105-33, § 4001, 111 Stat. 251, 275, amended
by Medicare Prescription Drug, Improvement, and Modernization Act of 2003 § 101, 117
Stat. at 2071.
162. Medicare Prescription Drug, Improvement, and Modernization Act of 2003 § 201,
117 Stat. at 2176.
163. U.S. Dep't of Health & Human Servs., Medicare Advantage Plans, http://
www.medicare.gov/choices/advantage.asp (last visited Oct 18, 2009).
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comparison information and the opportunity to choose. 164
b. Medicaid
The Medicaid program helps 59 million low-income individuals access
health care services through state-administered programs with joint Federal
and State funding. 165 All state Medicaid programs cover prescription
drugs,166 but they vary widely in their prescription drug coverage. 167 States
can place caps on prescription drug reimbursement,1 68 impose cost
containment measures such as co-pays, 16 9 designate categories of preferred
drugs,1 70 limit the number of prescriptions that can be filled, 171 and form
multi-state purchasing coalitions to negotiate with pharmaceutical
manufacturers.1 72 In 2006, Medicaid funded nine percent of the $217 billion
of the total national spending on prescription drugs, over $19 billion.173 The
Medicaid program does not purchase drugs directly. State Medicaid
agencies reimburse retail pharmacies that dispense prescription drugs to
Medicaid beneficiaries. 174 The pharmaceutical manufacturer then pays the
state agency a rebate calculated according to a formula defined by statute. 1"
In 1990, Congress established the Medicaid rebate system to lower net
drug costs for states. 176 Manufacturers were allowed to enter into rebate
164. Tricia Newman et al., Kaiser Fam. Found., Prescription Drug Benefit Under
Medicare: Background Brief, http://www.kaiseredu.org/topics-im.asp?id=131&irnlD =
1 &parentlD=66 (last visited Oct. 18, 2009).
165. KAISER FAM. FOUND., MEDICAID: A PRIMER 1-3 (2009), http://www.kff.org/
medicaid/upload/7334-03 .pdf
166. Id. at 10.
167. Id. at 12.
168. Id.
169. Id.
170. Steven Soumerai, Benefits and Risks of Increasing Restrictions On Access to Costly
Drugs in Medicaid, 23 HEALTH AFF. 135, 135 (2004).
171. Id. at 135-36.
172. See BRENDAN KRAUSE, NGA CTR. FOR BEST PRACTICES, STATE PURCHASING POOLS
FOR PRESCRIPTION DRUGS: WHAT'S HAPPENING AND How Do THEY WORK? (2004),
http://www.nga.org/cda/files/0408PRESCRIPTION.pdf.
173. KAISER COMM'N ON MEDICAID AND THE UNINSURED, KAISER FAM. FOUND., THE
MEDICAID PROGRAM AT A GLANCE 1 (2008), http://www.kff.org/medicaid/upload/7235-03-
2.pdf.
174. Letter from John E. Dicken, Director, Health Care, Gov. Accountability Office, to
Joe Barton, Chairman, Comm. on Energy & Commerce, H. of Rep. (Dec. 22, 2006),
http://www.gao.gov/new.items/d07239r.pdf.
175. Center for Medicare and Medicaid Services, U.S. Dep't of Health & Human Servs.,
Overview Medicaid Drug Rebate Program, http://www.cms.hhs.gov/
MedicaidDrugRebateProgram/ (last visited Oct 18, 2009).
176. U.S. Gov. ACCOUNTABILITY OFFICE, GAO-05-102, MEDICAID DRUG REBATE
PROGRAM (2005), http://www.gao.gov/new.items/d05l02.pdf.
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agreements with the Department of Health and Human Services. 177 States
could receive federal matching payments for prescription drugs only from
manufacturers that entered into such agreements.
171
Most states calculate rebates based on the AWP.179 Ceilings are
established for certain multiple-source Medicaid drugs by the Federal
Upper Limit (FUL) or State Maximum Allowable Cost programs.18 ° The
Deficit Reduction Act of 2005 attempted to change the basis for calculating
the FUL to Average Manufacturer Price (AMP)18 1 and to require CMS to
share AMP data with states, but an injunction and the Medicare
Improvements for Patients and Providers Act of 2008 (MIPPA) delayed
implementation.18 2 Thus, FUL is still calculated based on the lowest
published prices (AWP or wholesale acquisition cost (WAC)'83), which the
Office of the Inspector General believes may result in inflated payments for
Medicaid prescription drugs. 1
84
177. DANIEL R. LEVINSON, U.S. DEP'T OF HEALTH & HUMAN SERVS., OEI-03-07-00350,
COMPARING PHARMACY REIMBURSEMENT: MEDICARE PART D TO MEDICAID 5 (2009),
http://oig.hhs.gov/oei/reports/oei-03-07-00350.pdf
178. KAISER COMM'N ON MEDICAID AND THE UNINSURED, KAISER FAM. FOUND.,
MEDICAID AND PRESCRIPTION DRUGS 2 (2000), http://www.kff.org/medicaid/loader.cfm?url=
/commonspot/security/getfile.cfm&PagelD = 13591.
179. LEVINSON, supra note 177, at i.
180. Id.
181. The Average Manufacturer Price (AMP) is a benchmark that Congress created in
1990 for calculating Medicaid rebates. It is not publicly available. The AMP represents the
average price wholesalers pay manufacturers for drugs distributed to retail pharmacies.
According to the Congressional Budget, AMP is an estimated 20 percent lower than AWP
for approximately 200 pharmaceuticals frequently purchased by Medicaid beneficiaries.
Health Res. & Servs. Admin., U.S. Dep't of Health & Human Servs., Pharmacy Affairs &
340B Drug Pricing Program, http://www.hrsa.gov/opa/glossary.htm (last visited Oct. 18,
2009) [hereinafter Pharmacy Affairs & 340B Drug Pricing Program].
182. Medicare Improvements for Patients and Providers Act of 2008, Pub. L. No. 110-
275, 122 Stat. 2494 (2008) (prohibits CMS from imposing FULs for multiple source drugs
prior to October 1, 2009); see also Ctr. for Medicare & Medicaid Servs., U.S. Dep't of
Health & Human Servs., Federal Upper Limits, http://www.cms.hhs.gov/Reimbursement/
05_FederalUpperLimits.asp (last visited Oct. 18, 2009).
183. The WAC is"... the manufacturer's list price for the drug to wholesalers or direct
purchasers, not including prompt pay or other discounts, rebates, or reductions in price, for
the most recent month for which information is available." ROBERT A. VITO ET AL., DEPT. OF
HEALTH & HUMAN SERVS., OEI-03-05-00200, MEDICAID DRUG PRICE COMPARISON:
AVERAGE SALES PRICE TO AVERAGE WHOLESALE PRICE 2 (2005), http://oig.hhs.gov/
oei/reports/oei-03-05-00200.pdf; see Pharmacy Affairs & 340B Drug Pricing Program,
supra note 181.
184. VITO ET AL., supra note 183, at ii; see also Alex Sugarman-Brozan & James
Woolman, Drug Spending and the Average Wholesale Price: Removing the A WP Albatross
from Medicaid's Neck, 13 HEALTH CARE POL'Y REP. 1177 (2005), available at
http://healthcenter.bna.com/pic2/hc.nsf/id/BNAP-6G8NPZ.
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c. 340B Programs
Established in 1992 by the Veterans Health Care Act of 1992,185 the
340B program allows certain federally-funded grantees and other safety net
providers to purchase prescription drugs at reduced prices.186 In 2005, 340B
entities spent $4 billion on outpatient prescription drugs. 187
Drug companies entitled to sell their products under Medicaid must agree
to sell their products to 340B covered entities at a reduced price. 88 The
program results in significant savings on prescription drugs for entities
including Federally Qualified Health Centers, Disproportionate Share
Hospitals, the Indian Health Service, and Centers for Disease Control
entities treating sexually-transmitted diseases and tuberculosis.18 9
The "340B Ceiling Price" requires discounts of at least fifteen percent of
the AMP for brand-name drugs and eleven percent of the AMP for
generics. 190 Covered entities can negotiate sub-ceiling prices. A "prime
vendor" is selected to negotiate favorable prices for 340B entities.1 91
d. FSS
The Federal Supply Schedule (FSS) is a group of multiple award
contracts with various vendors.1 92 These contracts are used by federal
agencies and other government entities to purchase goods and services,
including prescription drugs. 193 The Veterans Administration (VA)
negotiates the FSS pharmaceutical schedule based on prices drug
manufacturers charge their "most-favored" non-federal purchasers.
194
Manufacturers cannot charge the VA, Department of Defense (DOD),
Public Health Service (PHS), and Coast Guard more than the Federal
Ceiling Price (FCP) for brand-name drugs.1 9 5 The FCP must be twenty-four
percent or more below the non-Federal AMP. 196
185. Veterans Health Care Act of 1992, 42 U.S.C § 256b (2006).
186. Hearing on the 340B Drug Pricing Program Before the Subcomm. on Oversight &
Investigations of the H. Comm. on Energy & Commerce, 109th Cong. (2005) (statement of
Stuart Wright, Deputy Inspector General for Evaluation and Inspections, Office of Inspector
General., U.S. Department of Health and Human Services, available at
http://oig.hhs.gov/testimony/docs/2005/340bHouseE&C 12-05.pdf
187. Id.
188. KAISER FAM. FOUND., PRESCRIPTION DRUG TRENDS (2008), http://www.kff.org/
rxdrugs/upload/3057_07.pdf
189. Pharmacy Affairs & 340B Drug Pricing Program, supra note 181.
190. Id.
191. Id.
192. Id.
193. Id.
194. Id.
195. Id.
196. Id.
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e. Veterans Administration
The Veterans Administration (VA) offers veterans medical benefits that
include an outpatient drug benefit with lower out-of-pocket costs than is
available to Medicare beneficiaries under Part D. VA pharmacies fill
prescriptions for an $8 (in 2007) co-payment with no deductible, no cap,
and no doughnut hole,197 and the prices the VA obtains for their formulary
are frequently the lowest available in the nation. 198 Additionally, the VA
imposes price ceilings on certain drugs. 199 The drugs must be prescribed by
a VA provider and filled at a VA pharmacy or through the VA's mail order
pharmacy.200 In 2005, the VA spent $4.2 billion on pharmaceuticals. 20 1 The
VA negotiates with manufacturers for discounts and uses blanket purchase
agreements to negotiate prices below those available under FSS. It further
reduces prices by using preferred drug distributors known as prime vendors
to purchase drugs and deliver them to VA facilities; the VA receives further
discounts through prime vendors.20 2
3. Pharmaceutical Assistance Programs
A number of programs supported by states, nonprofit organizations, and
pharmaceutical manufacturers offer help in accessing and affording
prescription drugs for individuals who lack insurance coverage. 203 Some of
these organizations have recently increased the assistance that they offer.20 4
Information about pharmaceutical assistance programs is available by
telephone or online.20 5
E. Pharmaceutical Pricing Dynamics
The health care industry is comprised of a variety of business entities.
197. Austin B. Frakt et al., Controlling Prescription Drug Costs: Regulation and the
Role of Interest Groups in Medicare and the Veterans Health Administration, 33 J. HEALTH
POL. PoL'Y & L. 1079, 1081 (2008).
198. Pharmacy Affairs & 340B Drug Pricing Program, supra note 181.
199. John E. Dicken, Prescription Drugs: An Overview of Approaches to Negotiate
Drug Prices Used by Other Countries and U.S. Private Payors and Federal Programs,
Testimony before the Committee on Finance, U.S. Senate, General Accounting Office GAO-
07-358Tat 2 and 8 (Jan. 11, 2007).
200. Id. at 8.
201. Id. at6.
202. Id. at 12-13.
203. Kevin Sack, Slump Pushing Cost of Drugs Out of Reach, N.Y. TIMES, June 4, 2009,
at Al.
204. Francesca Lunzer Kritz, Get Help Paying for Drugs, L.A. TIMES, Mar. 30, 2009, at
E3.
205. See Partnership for Prescription Assistance, www.pparx.org (last visited Nov. 10,
2009); RxAssist, www.rxassist.org (last visited Nov. 10, 2009); NeedyMeds,
http://www.needymeds.org (last visited Nov. 10, 2009).
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Most hospitals are not-for-profit corporations, and physicians' offices and
group practices tend to be member-owned small business entities.2 °6
Disease-specific nonprofit organizations raise money to fund research, raise
awareness, disseminate information about diagnosis and symptoms, and
subsidize the cost of treatment. Manufacturers of devices and
pharmaceuticals, their wholesalers, pharmacy chains, health insurance
companies, and employers that sponsor health plans tend to be large, for-
profit entities with an obligation to their shareholders to maximize profits
and secure a return on investment. Drug companies develop pricing policies
to increase revenue and market share, utilizing various pricing strategies
over time to influence prescriber and consumer behavior.
1. First Entry, Patented, and Single Source Drugs
Patent protection is important to the pharmaceutical industry because of
the enormous cost of R&D and the ease with which a new drug, once
developed, can be manufactured by generics manufacturers; the innovator's
profit depends on its right to patent protection.20 7 The pharmaceutical
industry's economic structure and ability to obtain financing depend on its
ability to secure patents for new products.20 8
A pharmaceutical manufacturer that holds a monopoly position with
respect to a drug, whether due to patent protection or because there is no
other drug in its class, can charge what the market will bear. The prices of
specialty drugs, prescription medications used to treat rare disorders, tend to
be high even if their patents have expired because there are frequently no
competing drugs. Some specialty drugs are granted exclusive marketing
rights for a longer period under federal "orphan drug" laws.209
Examples of highly priced specialty drugs include the products of the
biotechnology corporation Genzyme, which markets drugs for very small
groups of patients with rare disorders. Genzyme charges patients with
210Gaucher disease as much as $200,000 a year for Cerezyme. 21 Only 5,000
patients in the world use the drug, which had $1.1 billion in sales in 2007.211
Ovation Pharmaceuticals Inc. also specializes in pharmaceuticals for rare
medical conditions. In 2005, it purchased the U.S. rights to Indocin, a drug
for babies born with the heart defect patent ductus arteriosus (PDA) and
206. Field, supra note 3.
207. Id.
208. Id.
209. See 21 U.S.C. § 360cc (2006).
210. Larkin, supra note 129.
211. Editorial, When a Drug Costs $300,000, N.Y. TIMES, Mar. 23, 2008, Editorial
Desk, at 8.
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raised its price from $26 to $36 per vial.212 The following year Ovation
purchased NeoProfen, the only drug that competed with Indocin, and priced
NeoProfen at $483 a vial.213 Questcor Pharmaceuticals recently raised the
price of H.P. Acthar Gel, used to treat children with a severe form of
epilepsy, from $1,600 a vial to $23,000.214 Solaris, a specialty drug for a
215rare blood disorder, can cost $389,000 a year.
2. Subsequent Entry or "Me-Too" Drugs
The first pharmaceutical product in its classification commands a high
price due to market exclusivity. If the product is patented, the second entry
into the market must either challenge the patent or utilize a formulation that
does not infringe on the patent. To compete, second and subsequent non-
infringing entries, or "me-too" drugs, must either provide a lower price or a
better outcome. 216 While the introduction of me-too drugs can thus provide
lower-cost options, they do not always lead to a reduction in the price of the
first entry, even though the appearance of me-too drugs can lead payors to
place first entry drugs whose prices remain high into higher formulary tiers.
The manufacturer of a first entry drug may elect to retain its high price
point with the expectation that physicians and patients will be reluctant to
discontinue a medication that has worked, preferring to sell the product at a
high price to a smaller number of patients rather than selling it to more
patients at a lower price.217
3. First Generic Entry
The first generic to enter the market of a brand-name drug generally
enters at a seventy to eighty percent of the price of its brand-name
218counterpart, and in a short time it can acquire a substantial market share.
Due to the Hatch-Waxman Act, the first generic entry may be entitled to a
180-day period of market exclusivity, sharing the market with the brand-
212. Jonathan D. Rockoff, FTC Sues Ovation in Dispute on Drug Prices, WALL ST. J.,
Dec. 17, 2008, at B3.
213. Id (The Federal Trade Commission has filed suit to prevent Ovation from owning
both NeoProfen and Indocin, and to disgorge profits, alleging unfair competition).
214. Milt Freudenheim, The Middleman's Markup, N.Y. TIMES, Apr. 19,2008, at Cl.
215. Id.
216. Thomas H. Lee, "Me-Too" Products Friend or Foe?, 350 NEWENG. J. MED. 211,
211 (2004).
217. Id. at 212.
218. Protecting Consumer Access to Generic Drugs: The Benefits of a Legislative
Solution to Anticompetitive Patent Settlements in the Pharmaceutical Industry: Hearing
Before the Subcomm. on Commerce, Trade, and Consumer Protection of the H. Comm. on
Energy and Commerce, 110th Cong. 7 (2007) (statement of the Federal Trade Commission),
available at http://www.ftc.gov/os/testimony/P859910%2OProtecting Consume 0/20
Access testimony.pdf [hereinafter FTC Prepared Statement].
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name drug to which it is equivalent and gaining substantial profits.219
4. Subsequent Generic Entries
Generics that enter the market second or subsequent to the first entrant
must compete on price and often discount eighty percent or more off the
price of the brand-name drug, prompting generics that entered earlier to
lower their prices,220
IV. TRENDS IN THE PHARMACEUTICAL INDUSTRY
THAT AFFECT ACCESS
A. The Patent Cliff and the Shrinking Pipeline
According to IMS Health, prescription drugs with sales approximating
$120 billion will lose patent protection by 2013, including ten of the top 20
brand-name drugs.221 By 2016, pharmaceutical companies are expected to
lose $140 billion in annual sales due to patent expiration and the entry of
generics.22 2
The impact of this "patent cliff' is heightened by the relatively few
potential blockbuster drugs currently in the developmental pipeline of
innovator pharmaceutical companies. The FDA approved more drugs in
2008 than in each of the prior three years, but few of the new drugs appear
likely to be blockbusters.223
Although innovator manufacturers more than doubled spending on R&D,
they brought to market 43 percent fewer new pharmaceuticals between
2002 and 2006 than they did between 1995 and 2000, and drugs currently
under development lack the commercial potential of earlier drug
pipelines.224
As a result, the pharmaceutical industry is employing strategies to
expand revenue from existing product lines, such as raising prices (the
average price per pill has increased 63 percent since 2002)225 and increasing
marketing. Advertising spending increased from $2.5 billion in 2001 to $5.3
billion in 2006, and the number of industry sales reps has nearly tripled
since 1995 .226 Pharmaceutical innovators are also more likely to own
219. Avery, supra note 12.
220. FTC Prepared Statement, supra note 218.
221. Pettypiece, supra note 102.
222. Reuters UK, Drugmakers warned of $140 billion patent "cliff," Mar. 5, 2009,
http://uk.reuters.com/articlePrint?articleld=UKGR122300720070502.
223. Jared A. Favole & Jennifer Corbett Dooren, FDA Approved More Drugs in 2008,
WALL ST. J., Jan. 2, 2009, at A9.
224. Martinez & Goldstein, supra note 93.
225. Id.
226. Id.
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generic subsidiaries or contract with generics manufacturers for the
production of "authorized generics.'
227
B. Slowing Growth in Demand for Prescription Drugs
The patent cliff is one factor mitigating drug spending growth: the
availability of generic versions of blockbuster name-brand drugs is
expected to lead to more moderate spending growth in 2012 and 2013.228
The growth of demand for pharmaceuticals is already experiencing a
slowdown due to the availability of generics, safety concerns arising out of
recent FDA warnings,229 a leveling-off in the pace of Medicare drug
spending following the Part D launch in 2006, 230 fewer new drugs being
approved by the FDA, and fewer new blockbuster drugs in development by
pharmaceutical innovators. 231 The slowdown is expected to continue as
consumers cut back on medicines due to lack of insurance coverage or
increased co-pays and deductibles. 2
By 2007, pharmaceutical spending growth had slowed to the lowest rate
in forty-five years. 3 In 2009, IMS Health expects the drug industry to
grow less than two percent. 4 Layoffs in the pharmaceutical industry
appear to confirm these projections: Pfizer, AstraZeneca, Johnson &
Johnson, and Glaxo have recently announced layoffs, and the wealth
management company RegentAtlantic Capital expects that perhaps 50,000
pharmaceutical industry jobs will be lost in the next ten years. 5
The current recession has impacted growth in demand for
pharmaceuticals as consumers switch to generics or fill fewer prescriptions.
However, a recession can also lead to increased enrollment in government
227. Stephanie Saul, More Generics Slow the Surge in Drug Prices, N.Y. TIMES, Aug. 8,
2007, at Al.
228. Andrea Sisko et al., Health Spending Projections Through 2018: Recession Effects
Add Uncertainty to the Outlook, 28 HEALTH AFFAIRS w346, w350 (2009).
229. Bruce Japsen, Safety Fears Help Put Brakes On Prescription Drug Growth, CHI.
TRiB., Jan. 8, 2009, at C25.
230. Vanessa Fuhrmans & Jane Zhang, U.S. News: Health-Care Outlays Climb at
Slowest Rate in Years, WALL ST. J. Jan. 6, 2009, at A4.
231. IMS Health New Report Highlights Dramatic Change in U.S. Drug Spending
Trends, Policy Implications, Dec. 23, 2008 http://www.imshealth.com/portal/site/imshealth/
menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=841365272046e 110VgnVCM
100000edl 52ca2RCRD&vgnextchannel=4la67900b55a51 1OVgnVCM 10000071812ca2RC
RD&vgnextfmt-default.
232. Fuhrmans & Zhang, supra note 230.
233. Id.
234. Ceci Connolly, With More Oversight on the Horizon, Drugmakers Work to Polish
Image, WASH. POST, Jan. 8, 2009, at AOl.
235. See Martinez & Goldstein, supra note 93; see also Scott Hensley, Reports: Glaxo
Prepares to Ax 6,000 More Jobs, WALL ST. J. HEALTH BLOG, Feb. 2, 2009, http://
blogs.wsj.com/health/2009/02/02/reports-glaxo-prepares-to-ax-6000-more-jobs/.
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health programs, which can offset a decrease in private spending.236 The
generics dispensing rate is expected to level off between 2014 and 2018,
and new drug approvals are expected to drive the growth of drug spending,
particularly in the market for specialty drugs,237 whose prices are increasing
much faster than prices of pharmaceuticals.238
Comparative effectiveness analysis, a process by which researchers
compare various medical treatments for the same illness, may further
decrease the demand for prescription drugs that prove ineffective relative to
other treatments. The recently passed $787 billion economic stimulus bill
allocates $1.1 billion for comparative effectiveness analysis in an effort to
save health care costs by discouraging the use of ineffective treatments. 2
39
"Personalized medicine," another development that promises to decrease
demand for pharmaceuticals, involves genetic screening and other tests that
could enable doctors to design treatment regimens for individual patients.24 °
Such treatments could improve care and decrease costs. It is estimated that
prescription drugs work for only about half the people for whom they are
prescribed, wasting much of America's approximately $300 billion annual
spending on pharmaceuticals and exposing many patients to the side effects
of drugs that do not improve their conditions.241
Although there is currently no system in place to approve genetic tests
for drug effectiveness or to evaluate their accuracy, when such testing
becomes available pharmaceutical manufacturers could lose market share
for each product that becomes the subject of a genetic test with the capacity
to determine that a drug is inappropriate for a portion of a population of
patients with a given condition.242 The blockbuster model, which has led
pharmaceutical manufacturers to focus on new drugs that promise to
command high prices in large markets, is vulnerable to advances in
genomics, which could lead to increasingly personalized medicine and
smaller markets for individual drugs.
243
236. CTRS. FOR MEDICARE AND MEDICAID SERVS., NATIONAL HEALTH EXPENDITURES
PROJECTIONS 2008-2018 2 (2008), http://www.cms.hhs.gov/NationalHealthExpendData/
downloads/proj2008.pdf.
237. Sisko et al., supra note 228, at w354-55.
238. Freudenheim, supra note 214.
239. Robert Pear, U.S. to Study Effectiveness of Treatments, N.Y. TIMES, Feb. 16, 2009,
at Al [hereinafter Pear, U.S. to Study Effectiveness].
240. Andrew Pollack, Patient's DNA May be Signal to Tailor Drugs, N.Y. TIMES, Dec.
30, 2008, at Al.
241. Id.
242. Id.
243. Field, supra note 3, at 258.
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C. The Financial Outlook for Pharmaceutical Companies
Pharmaceutical industry revenue is expected to decline between 2011
and 2012 for the first time in forty years.244 Growth in demand for
pharmaceuticals is slowing.245 The pharmaceutical industry is likely to face
increased costs due to liability exposure as a result of the U.S. Supreme
Court's ruling in Wyeth v. Levine246 that state liability for failure to warn of
a product's dangers is not preempted by federal law regarding FDA
approval of a product's warning label. Specialty drug prices are increasing
faster than those of pharmaceuticals 247 and the potential of biotechnology is
affecting the financial outlook for the pharmaceutical industry. In spite of
the financial risks associated with the development of biotech drugs, the
outlook for the biotechnology industry may be more promising than for
pharmaceuticals, as evidenced by the increase in value of the shares of a
number of large biotech corporations in 2008.248 For example, Wyeth
reported in January 2009 that its revenue from products such as vaccines
and biotech drugs is outpacing revenue growth from traditional
pharmaceuticals.2 49 Pfizer, Inc. Chairman and Chief Executive Jeffrey
Kindler said Pfizer's $68 million acquisition of Wyeth in January 2009 was
part of its new focus: transitioning from developing blockbuster drugs to
biotechnology.
Consequently, the pharmaceutical industry appears to be shifting its
emphasis from pharmaceuticals to biotechnology products: since 2005,
large drug companies have spent almost $76 billion to buy biotechnology
companies.25 1 Drug company interest in biotechnology may be due in part
to the lack of generic competition in the biotech market. Biotechnology
products are difficult for generics manufacturers to reproduce because they
are made from living tissue. Moreover, the United States currently has no
approval process for generic biotechnology drugs.
252
244. Martinez & Goldstein, supra note 93.
245. See Japsen, supra note 229.
246. Wyeth v. Levine, 129 S. Ct. 1187, 1204 (2009).
247. Freudenheim, supra note 214, at C1.
248. See Damian Troise, Biotech Proves Defensive Against Tough 2008 Market, S.F.
CHRONICLE, Dec. 31, 2008, http://www.sfgate.com/cgi-bin/article.cgi?f=/rna/2008/12/31/
financial/f062301S40.DTL.
249. Linda A. Johnson, Wyeth Exec: Nontraditional Products Fueling Growth,
NETSCAPE MONEY & Bus., Jan. 14, 2009, http://webcenters.netscape.compuserve.com/pf/
story.jsp?floc=FF-APO-1333&idq-/ff/story/0001%2F20090114%2F 1534270437.htm&sc-
1333.
250. Bruce Japsen, Pfizer's Future Tied to Biotechnology, CI. TRIB. Feb. 12, 2009, at
C27.
251. Martinez & Goldstein, supra note 93.
252. Troise, supra note 248.
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V. INDUSTRY STRATEGIES THAT AFFECT PRICE AND ACCESS
A. Product Migration Pricing Strategy
Pharmaceutical manufacturers may price drugs strategically to "migrate"
demand from one product to another.253 "Product migration strategy"
involves using price to incent consumers to choose one product over
another, thus causing demand to "migrate.,
254
For example, Cephalon, Inc. raised the price of Provigil, a drug for
narcolepsy, twice in 2008, and by November 2008, the drug cost seventy-
four percent more than it did in 2004.255 This price increase impacts not
only the uninsured, but also insured patients who use Provigil for a disorder
other than narcolepsy (such as for Parkinson's disease) who may be
required to pay the increased price out-of-pocket if his or her insurer refuses
to pay for off-label drug use.2 56
The tactic appears to be intended to steer patients from the generic
competition that will enter the market in 2012. Cephalon plans to launch
Nuvigil, a longer-acting version of Provigil, in 2009. 257 By raising the price
of Provigil and launching Nuvigil at a lower price point than Provigil,
Cephalon may hope to migrate demand to the new, patent-protected drug,
for which there will be no generic equivalent. 8 The strategy could
undermine the market for the generic by thwarting state laws and health
plan policies mandating generic substitution: a pharmacy cannot
automatically substitute the generic form of Provigil when a patient
presents a prescription for Nuvigil. To compete with Nuvigil, the
manufacturer of the generic for Provigil may have to consider undertaking
its own marketing campaign because it may not be able to rely on
Cephalon's promotional activities and automatic substitution to lead to sales
of the generic. However, budgeting for promotional expenditures would
likely increase the cost of the generic.
B. Switching Prescription Drugs to Over-the-Counter Status
A pharmaceutical innovator may attempt to switch a brand-name product
to over-the-counter (OTC) status to compete against a new generic and to
expand its market by linking the OTC switch to a direct-to-consumer
253. Jonathan D. Rockoff, How a Drug Maker Tries to Outwit Generics, WALL ST. J.,
Nov. 18, 2008, at B1.
254. Reed Holden, Giving Generics a Headache With Pharma Pricing, (Nov. 18, 2008),
http://reedholden.wordpress.com/2008/11/18/giving-generics-a-headache-with-pharma-
pricing/.
255. Rockoff, supra note 253.
256. Id.
257. Id.
258. Id.
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advertising campaign alerting consumers to the product's availability
without a prescription. The information provided in the advertising,
packaging, and labeling must enable individuals to make informed decision
about product use and their possible need for medical oversight, particularly
for long-term treatment of chronic conditions.2 19 While such a move might
increase the market for the drug, it could raise costs for patients with
insurance whose prescription drug coverage does not cover OTC products.
The Durham-Humphrey Amendment to the Federal Food, Drug, and
Cosmetic Act provides that the FDA can approve a drug's exemption from
prescription dispensing requirements if the requirements are not necessary
to protect the public from the drug's toxicity, harmful potential, or its
method of use, and the drug is safe and effective to be used as directed for
self-medication. 260 A drug company is required to perform studies of label
comprehension and actual use before the FDA will approve a drug's switch
from prescription to OTC status, but the studies are short and relatively
small.261
C. Promotional Activities
Pharmaceutical companies promote their products through
communications and marketing campaigns that include advertising to
physicians, pharmacists, and consumers in order to attempt to increase the
size of the market for the drug or the drug's market share in the case of
multi-source products. Fewer promotional and advertising activities are
undertaken with respect to specialty drugs because they are used by a
smaller population.262
Pharmaceutical promotional activities include sales representative visits
and gifts to physicians, conferences, speeches, educational programs and
events, and televised or print direct-to-consumer (DTC) advertising. 263
Merck's extensive efforts to promote Gardasil, a vaccine against several
264types of human papillomavirus (HPV) that can cause cervical cancer,
illustrate the variety of marketing activities available to drug manufacturers:
Merck financed activities for women's groups, issued grants to train
speakers on college campuses, and provided kits to promote the vaccine at
259. See Tinetti, supra note 31, at 2730.
260. Durham-Humphrey Amendment, ch. 578, § 503(b)(1), 65 Stat. 648, 648 (1951)
(current version at 21 U.S.C. §§ 353-355 (2000)).
261. Tinetti, supra note 31, at 2729.
262. Martinez & Goldstein, supra note 93.
263. See JEROME P. KASSIRER, ON THE TAKE: How MEDICINE'S COMPLICITY WITH BIG
BusINEss CAN ENDANGER YoUR HEALTH (2005).
264. See Merck, Learn About Gardisil, http://www.gardasil.com/what-is-gardasil/
index.html (last visited Nov. 15, 2009).
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college health services.265
VI. PROPOSALS FOR REFORM
The reform proposals discussed below have been advanced with the goal
of improving the access and affordability of prescription drugs. Current
trends in the pharmaceutical industry and strategies employed by drug
companies to enhance the success and competitiveness of their products
will influence whether a reform proposal will be effective or whether it will
be easily circumvented by the industry's strategic reaction to its
implementation.
A. Proposals to Promote Generics
Generic drugs tend to be priced thirty to eighty percent less than
equivalent brand-name pharmaceuticals. As more generic substitutes for
brand-name drugs become available, consumers have the option of
choosing a lower-priced alternative for medications prescribed by their
treatment providers. The following reform proposals thus attempt to
increase drug affordability by facilitating generic development, promotion,
and market entry.
1. Prohibiting Reverse Payment Patent Litigation Settlements
Prior to generic entry, brand-name pharmaceutical companies and
generics manufacturers sometimes litigate the validity of a patent, or
whether it would be infringed upon by a proposed generic equivalent,
pursuant to the scheme developed under the Hatch-Waxman Act. The
litigants may settle such patent litigation by agreeing upon a market entry
date for the generic product, settlement payments from the innovator to the
generics manufacturer, or other settlement provisions such as licensing
agreements. Such agreements currently protect ten brand-name drugs with
U.S. sales totaling approximately $17 billion.266 The Federal Trade
Commission, has argued that such settlements amount to "pay for delay"
and hurt consumers by obstructing generic market entry while permitting
brand-name drugs to continue to charge monopoly prices.267 Because the
Hatch-Waxman Act allows the first generics challenger a 180-day period of
exclusivity, delaying the first challenger's market entry creates a
"bottleneck" that impedes the market entry of additional generics until 180
265. Elisabeth Rosenthal, Drug Makers 'Push Leads to Vaccine's Fast Rise, N.Y. TIMES,
Aug. 20, 2008, at Al.
266. Jonathan D. Rockoff, U.S. News: Democrats Target Deals to Delay Generics,
WALL ST. J., Mar. 31, 2009, at A3 [Hereinafter Democrats Target].
267. FTC Prepared Statement, supra note 218.
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days beyond the market entry date agreed upon in the settlement.268
Outside of the pharmaceutical industry, patent litigation is frequently
settled by agreements whereby the challenger pays the patent holder for a
license which can be limited in time or area. Settlements of patent litigation
filed pursuant to Hatch-Waxman, however, are sometimes referred to as
"reverse payment" settlements because the patent holder pays the
challenger.269
The FTC maintains that these settlements are highly profitable to brand-
name firms because they enable the continuation of monopoly profits until
the agreed-upon generic market entry date, as well as to generics firms
which can receive more in settlement payments than the anticipated profits
from the generic drug. However, reverse payment settlement can harm
consumers by delaying generic entry.270 The FTC has challenged such
settlements, arguing that they allow drug patent holders "to buy more
protection from competition than congressionally-granted patent rights
afford... [and] disrupt the careful balance between patent protections and
encouraging generics entry that Congress sought to achieve in the Hatch-
Waxman Act., 27 1 Access to Affordable Pharmaceuticals, Title XI of the
Medicare Reform Act of 2003,272 allows FTC review of settlements.
Critics of such settlements point out that the interests of the litigants are
aligned when settling patent infringement or invaliding litigation pursuant
to Hatch-Waxman,273 which could lead to settlements that benefit the
litigants at the expense of consumers. In support of the settlements,
commentators have pointed out that the law generally favors settlement of
litigation and that forcing companies to conclude litigation could stifle
274innovation. Moreover, reverse payment settlements have allowed
generics market entry prior to the expiration date of the litigated patent.
Proposed legislation to prohibit patent holders in the pharmaceutical
industry from compensating a generics manufacturer to delay market entry
of a generic drug characterizes such settlements as collusion contrary to free
competition. 275 The proposal would amend the Clayton Act276 to make
268. Avery, supra note 12, at 175-76.
269. Id. at 181.
270. See FTC Prepared Statement, supra note 218, at 11.
271. Id.
272. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, 21
U.S.C. § 355 (2006).
273. See C. Scott Hemphill, Paying for Delay: Pharmaceutical Patent Settlement as a
Regulatory Design Problem, 81 N.Y.U. L. REv. 1553, 1593-94 (2006).
274. Sheila Kadura, Is an Absolute Ban on Reverse Payments the Appropriate Way to
Prevent Anticompetitive Agreements Between Branded-and Generic-Pharmaceutical
Companies?, 86 TEx. L. Rav. 647, 664 (2008).
275. S. 316, ll0thCong. (2007).
276. 15 U.S.C. §§ 12-27 (2006).
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settlements of pharmaceutical patent infringement litigation unlawful if a
generics manufacturer that files an abbreviated new drug application
(ANDA)277 under the Hatch-Waxman Act receives anything of value and
agrees not to market the product for a period of time.
A blanket prohibition could have the unintended effect of discouraging
generics manufacturers from challenging patents under the Hatch-Waxman
Act because the ensuing litigation may need to proceed to a final court
decision and exhaust any possible appeals, thus increasing the time and
expense of such a challenge. Because the proposal refers to "the sale of a
drug product" with reference to definitions under FDA regulations, 278 it is
unclear whether it would apply to both pharmaceutical and biotechnology
products.
Pharmaceutical and generics manufacturers may be able to circumvent
prohibitions on reverse payment settlements by structuring the deals so that
no money changes hands between the parties. Medicis Pharmaceutical
Corp. recently settled litigation over the patent for its acne drug challenged
by generics manufacturer Teva Pharmaceutical Industries Ltd. with an
agreement that required Teva to delay selling its product until 2011. 279
However, Teva had already earned $25 million for sales of the generic prior
to settlement, and the agreement allowed it to keep this revenue.280 Similar
strategies could enable settlements that do not violate proposed prohibitions
but still benefit innovators and generics manufacturers at the expense of
consumers.
2. Generic Biotechnology Drugs
The Hatch-Waxman Act provides a regulatory scheme for approving
generic equivalents of brand-name pharmaceutical drugs, but the U.S. has
no comparable means for generics manufacturers to obtain approval to copy
a biotechnology drug.281 Generic biotech drugs could cost an estimated one-
277. The Hatch-Waxman Act (see Eurek, supra note 7) provides for the approval of
generic drugs by allowing a generics manufacturer to file an abbreviated new drug
application (ANDA). Whereas an innovator pharmaceutical company seeking approval of a
new drug must file a new drug application (NDA) proving the drug is safe and effective, the
ANDA can rely on the innovator's clinical trials, thereby saving research costs and
decreasing the cost of generics. Avery, supra note 12, at 175-76.
278. 21 C.F.R. § 314.3(b) (2008) ("Drug substance means an active ingredient that is
intended to furnish pharmacological activity or other direct effect in the diagnosis, cure,
mitigation, treatment, or prevention of disease or to affect the structure or any function of the
human body, but does not include intermediates use in the synthesis of such ingredient.").
279. Democrats Target, supra note 266.
280. Id.
281. A. Taylor Corbitt, The Pharmaceutical Frontier: Extending Generic Possibilities to
Biologic Therapies in the Biologics Price Competition and Innovation of Act of 2007, 18
DEPAUL J. ART, TECH. & INTELL. PROP. L. 365, 375-76 (2008).
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third less than their brand-name counterparts.282 High development costs
and tougher regulatory scrutiny for generic biologics are likely to increase
their prices relative to generic pharmaceuticals.283 Duke University health
economist Prof. Henry G. Grabowski predicts that prices for generic
biologics may decline less than for generic pharmaceuticals.284
The Biotechnology Industry Organization (BIO), a trade association for
the biotech industry, argues that generic biologics would decrease
incentives for R&D.285  However, the introduction of generic
pharmaceuticals after passage of the Hatch-Waxman Act in 1984 does not
appear to have stifled R&D. The Congressional Budget Office stated:
Between 1983 and 1995, investment in [R&D] as a percentage of
pharmaceutical sales by brand-name drug companies increased by 14.7
percent to 19.4 percent. Over the same period, U.S. pharmaceutical sales
by those companies rose from $17 billion to $57 billion (in current
dollars). Overall, then, the changes that have occurred since 1984 appear
to be favoring investment in drug development. 286
The biotechnology industry warns that biotech drugs are so complex that
an exact duplication is impossible to achieve; an attempted copy must be
tested in humans before it is approved as safe and effective. 28 7 Critics claim
that a difference in how a generic biologic is made in comparison with the
brand-name original could change its effect on the human body, possibly
decreasing its effectiveness or causing an allergic reaction.288
Due to the nature and complexity of biologic synthesis, minor changes in
biotech compounds could have serious consequences in humans.289 Since
perfect duplication is impossible, generic biologicals are referred to as
"biosimilars" rather than "bioequivalents.,, 290 A biosimilar may not be an
automatic substitute for the brand-name biologic.291 State laws mandating
282. Bill WouldAllow Copying of Biotech Drugs, N.Y. TIMES, Feb. 15, 2007, at C12.
283. Thomas Gryta, Tough Road for Biologics - Generic Makers Could Face High
Development, Marketing Costs, WALL ST. J., Mar. 4, 2009, at B4.
284. Pear, Congress Seeks Compromise, supra note 14.
285. Press Release, Biotechnology Industry Org., New Senate Bill Takes Shortcuts on
Path to Biosimilars (Mar. 26, 2009), http://www.bio.org/news/pressreleases/newsitem.asp?id
=2009 0326 01.
286. CONGRESSIONAL BUDGET OFFICE, How INCREASED COMPETITION FROM GENERIC
DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY ix, xv
(1998), available at http://www.cbo.gov/ftpdocs/6xx/doc655/pharrn.pdf.
287. Pear, Congress Seeks Compromise, supra note 14.
288. Catherine Larkin, Obama Plan to Copy Biotech Drugs May Get Early Push
(Update2), BLOOMBERG, Mar. 10, 2009, http://www.bloomberg.com/apps/news?pid =
206011 10&sid=a4qYpDq065gO.
289. Corbitt, supra note 281, at 366-67.
290. Gryta, supra note 283.
291. Id.
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generic substitution may not apply to biosimilars.292 Dr. Janet Woodcock,
chief medical officer of the Food and Drug Administration, told Congress
that the FDA is capable of determining the human and laboratory tests
needed to approve generic biotech drugs.293
In the U.S., biologics are approved by the Public Health Service (PHS)
rather than the FDA.294 Proposed legislation to provide a regulatory
structure for the approval of biosimilars295 would amend the Public Health
Service Act to allow for the filing of an Abbreviated Biological Product
Application proving a product "comparable or interchangeable with the
reference product" 296 which would be reviewed by the FDA. The proposal
provides for a 180-day period of market exclusivity.2
97
Legislation to regulate generic biologics was reintroduced by
Representative Henry Waxman, who chairs the House Energy and
Commerce Committee, on March 11, 2009.298 A similar bill was introduced
in the Senate on March 24, 2009.299 The bill gives brand-name biologics the
right to five years of guaranteed market exclusivity, in addition to patent
protection, and the biotech industry has argued for a fourteen-year
exclusivity period of data exclusivity to run concurrently with the patent
term. 30 0 The combination of the 180-day biosimilar exclusivity, patent
protection and innovator market exclusivity would render the regulatory
scheme vulnerable to reverse payment settlements.
3. Proposal to Ban Authorized Generics
Proposed legislation3"1 would prohibit brand-name pharmaceutical
companies from marketing authorized generic versions of their products on
the grounds that authorized generics harm consumers by decreasing the
incentives for generics manufacturers to enter the market. 302
292. Id.
293. Pear, Congress Seeks Compromise, supra note 14.
294. 42 U.S.C. § 262 (2007).
295. H.R. 1038, 110th Cong. (2007).
296. Id. § 3.
297. Id.
298. Alicia Mundy, Corporate News: Firms Prepare for a Fight Over Generic Drugs,
WALL ST. J., Mar. 12, 2009, at B4.
299. Gardiner Harris, Bill Would Let Copycats Compete With Biotech Drugs, N.Y.
TIMEs, Mar. 27, 2009, at A17.
300. Press Release, Biotechnology Industry Org., Setting the Record Straight: Generic
Drug Industry Lobby 'Flat Out Wrong' About BIO Position on Follow-On Biologics (Apr.
1, 2008), http://www.bio.org/news/pressreleases/newsitem.asp?id=2008_0401_02.
301. H.R. 806, 110th Cong. (2007); S. 438, 110th Cong. (2007).
302. Deborah Platt Majoras, Maintaining our Focus at the FTC: Recent Developments
and Future Challenges, in Protecting Consumers and Competition, Keynote Address Before
the ABA Section of Antitrust Law 7th Annual Forum, (Nov. 15, 2007) (transcript available
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4. Follow-on Drugs
When faced with an expiring patent or a patent challenge from a generics
manufacturer, brand-name pharmaceutical manufacturers can develop a
new formulation for the product (for example, an extended release version
or a formulation that does not need to be taken with food), obtain a patent,
and migrate demand through pricing to the new formulation. Such a product
is sometimes called a "follow-on" drug, and the technique is referred to as
"'product hopping."30 3 If the brand-name manufacturer proceeds to
discontinue the original version of the drug, it can thwart generic
competition that relies on state laws or insurance company policies
requiring automatic substitution, because physicians will no longer be able
to prescribe the formulation for which there is a generic. The generics
manufacturer would be required to brand and promote its product to
prescribers, adding substantially to its costs. The FTC is investigating
follow-on drugs to determine whether improvements they offer consumers
are offset by their anticompetitive potential.3 °4
5. Public Education Campaigns to Encourage Use of Generics
Lower generics prices can benefit consumers, but barriers to information
about generic pharmaceuticals may prevent consumers from accessing these
medications.3 °5 According to one study, ". . .one-third of the most expensive
medications used by Medicare beneficiaries who exceeded their pharmacy
benefits in managed care plans had generic equivalents or a lower cost
therapeutic alternative. .."306 Prescribers, consumers, and physicians
frequently lack accurate information about prescription drug prices and
quality that would enable them to make cost-effective choices.
30 7
An estimated $2.76 billion could be saved through an education program
such as the "Consumer Reports Best Buy Drugs Program" if "Best Buy"
drug selections were fully substituted in the four classes of cardiovascular
medications studied.30 8 The Consumer Reports program is "a national
educational program that provides consumers with price and effectiveness
information on prescription drugs.
30 9
at http://www.ftc.gov/speeches/majoras/071115fall.pdf).
303. Jessie Cheng, An Antitrust Analysis of Product Hopping in the Pharmaceutical
Industry, 108 COLUM. L. REv. 1471, 1471 (2008).
304. Majoras, supra note 302.
305. Donohue et al., supra note 64, at 1557.
306. Id. at 1558.
307. Id.
308. Id. at 1565.
309. Id. at 1557.
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The FDA Amendment Act of 2007310 may improve consumer access to
information about drug safety and effectiveness through a data bank of
clinical trials that will be accessible to consumers. The Amendments are
"intended to provide a mechanism for the public to learn about clinical trials
that are being conducted, as well as the results of those trials '311 and enable
the FDA to require post-approval surveillance of pharmaceuticals. It is
uncertain whether the data bank will ultimately help consumers afford
prescription drugs by enabling them to make choices regarding the cost
effectiveness of treatment. Cost effectiveness research, discussed in Section
VI.E. below, may also yield information that would enable consumers and
their physicians to choose pharmaceutical treatment options that decrease
costs and improve outcomes.
Communicating information to physicians, other providers, and
prescribers about generics availability and other cost-effective drug
treatment strategies could also promote consumer access and
pharmaceutical affordability. Physicians currently receive information
about drugs from pharmaceutical companies through print media,
conferences and events, and visits from sales representatives or "detailers."
Pennsylvania has implemented a "counter-detailing program" that employs
"academic detailers" to visit physicians and promote evidence-based
medicine by providing research from Harvard University about drug cost
and effectiveness.312 Similar programs are underway in Vermont and
Mississippi. Vermont will also participate in a multi-state effort with Maine
and New Hampshire.
313
B. Importation and re-importation ofpharmaceuticals
The Obama-Biden health plan proposed lowering costs by increasing
competition in the drug and insurance industries; one element in the plan
would allow consumers to "import safe drugs from other countries."
314
Almost eighty percent of American adults, who pay higher out-of-pocket
310. Food and Drug Amendment Act of 2007, Pub. L. 110-85, 121 Stat. 823.
311. Mary Ann Liebert, Draft Guidance for Sponsors, Industry, Researchers,
Investigators, and Food and Drug Administration Staff: Certifications to Accompany Drug,
Biological Product, and Device Applications/Submissions: Compliance with Section 402(J)
of the Public Health Service Act, Added by Title VIII of the Food and Drug Administration
Amendments Act of 2007, 27 BIOTECHNOLOGY L. REP. 336, 336 (2008).
312. Rachel Brand, Marketing Drugs: Debating the Real Cost, STATE LEGISLATORS,
Sept. 2008, at 26, 26, available at http://www.ncsl.org/Portals/l/documents/magazine/
articles/2008/08SLsepO8_drugs.pdf.
313. Id. at 29.
314. Press Release, Barack Obama and Joe Biden's Plan to Lower Health Care Costs
and Ensure Affordable, Accessible Health Coverage for All, http://www.barackobama.com/
pdf/issues/HealthCareFullPlan.pdf.
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medical expenses than consumers in many industrialized countries,
315
support the idea of purchasing drugs from Canada. 316 If Americans were to
pay drug prices comparable to other industrialized nations, the savings
would be sufficient to close the Medicare Part D doughnut hole.317
Under the Food Drug and Cosmetic Act (FDCA), interstate shipment of
drugs lacking required FDA approval is illegal, with limited exceptions for
personal use.318 However, importation occurs through state programs that
facilitate such purchases through Web links to foreign pharmacies 319 and
bus tours to Canada for the purpose of purchasing medication.
320
The Pharmaceutical Market Access Act of 2009321 would amend the
FDCA to require the Secretary of the United States Department of Health
and Human Services (HHS) to promulgate regulations that would permit
pharmacies and wholesalers to import qualifying pharmaceuticals from
certain countries.322 The proposal would require that HHS inspect
importers' and exporters' facilities and records and educate consumers
about drug importation.32 3 The proposal would also implement anti-
counterfeiting packaging requirements. 324 Pharmaceutical companies would
be unable to allege patent infringement against importers of licensed
patented drugs first sold abroad. The act would prohibit drug manufacturers
from discriminating against importers by denying them supplies of drugs or
charging them higher prices.325
Critics of drug importation argue that safety is compromised by the
introduction of counterfeit drugs into the marketplace.326 Counterfeits can
endanger patients because they are ineffective or because they are made
from dangerous or even toxic ingredients.327 It is also difficult to monitor
imported drugs for modified expiration dates and to ensure that drugs with
315. Schoen et al., supra note 44, at 289.
316. KAISER SPOTLIGHT, supra note 29, at 18.
317. Karen Davis & Sara R. Collins, Medicare at Forty, 27 HEALTH CARE FINANCING
REV. 53, 57 (2005-2006), available at http://www.cms.hhs.gov/HealthCareFinancing
Review/downloads/05-06Winpg53.pdf.
318. FDA, Travelers Alert, http://www.fda.gov/Forlndustry/ImportProgram/
ucm173743.htm (last visited Nov. 10, 2009).
319. See, e.g., State of Wisconsin, Prescription Drug Resource Center, http://
www.drugsavings.wi.gov/ (last visited Nov. 10, 2009).
320. See Drug Bus - Canada Bound (NH Pub. Radio broadcast June 11, 2002),
available at http://www.nhpr.org/node/3249.
321. S. 80, 11lth Cong. § 1 (2009).
322. Id. § 3.
323. Id. § 4.
324. Id. § 505E.
325. Id. § 8.
326. See Brian A. Liang, A Dose of Reality: Promoting Access to Pharmaceuticals, 8
WAKE FOREST INTELL. PROP. L.J. 301, 303-04 (2007-2008).
327. Id. at 305-06.
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specific storage requirements have been properly handled during
transportation. Importation entrusts inspection responsibilities to the
governments of exporter nations, which may not undertake to ensure the
safety of drugs not intended for dispensation to their citizens.
Governmental policies of nations where prescription drugs are priced
lower than in the U.S. often involve the imposition of direct and indirect
price controls. Among the major industrialized countries, the U.S. is alone
in not regulating pharmaceutical prices.328
France and Italy regulate pharmaceutical prices directly through price
controls, Germany and Japan regulate drug prices indirectly, through
limits on reimbursement under various social insurance schemes, and the
United Kingdom employs profit controls to indirectly regulate prices.
329
According to the U.S. Department of Commerce, "[t]he principal
methods these governments employ are reference pricing, 330 approval
delays and procedural barriers, restrictions on dispensing and prescribing,
and reimbursement., 331 Certain governments that are members of the
Organisation for Economic Co-Operation and Development (OECD)332
establish sales prices and make it illegal to sell pharmaceuticals at any other
price, leverage their bargaining power as dominant market participant to
negotiate below-market prices, and establish reimbursement rates for new
drugs at levels far below market price in order to force consumers to bear
the difference between the market price and reimbursement level
(potentially shrinking the market for new drugs).333
Pricing policies that affect the market's supply side (manufacturers and
distributors) include: controlling the prices of individual products, reference
pricing, average pricing, imposing pricing constraints on sellers, and
formularies.334 Countries that regulate pricing on the demand side use
"... government regulated patient co-payments, advice, guidelines, and/or
budgets for physicians, parallel imports, and even the transfer of products
328. John A. Vernon et al., The Economics of Pharmaceutical Price Regulation and
Importation: Refocusing the Debate, 32 AM. J.L. & MED. 175, 176 (2006).
329. Id. at 176-77.
330. Id. at 177 ("reference pricing.., establishes a price based upon the price of the
same or similar drugs in other countries").
331. INT'L TRADE ADMIN., U.S. DEP'T OF COMMERCE, PHARMACEUTICAL PRICE
CONTROLS IN OECD COUNTRIES: IMPLICATIONS FOR U.S. CONSUMERS, PRICING, RESEARCH
AND DEVELOPMENT, AND INNOVATION viii (2004), available at http://www.ita.doc.gov/
td/chemicals/drugpricingstudy.pdf.
332. See Org. for Econ. Co-Operation & Dev., Member Countries, http://www.oecd.org/
countrieslist/0,3351,en_33873108_33844430 1 1 1 1 1,00.html (last visited Nov. 10
2009).
333. See INT'L TRADE ADMIN., supra note 331 at ix.
334. Vernon et al., supra note 328, at 177.
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from prescription-only to over-the-counter (OTC) status. 335
As an alternative to importation, the U.S. could analyze the practices of
other industrialized countries and adopt those policies that appear most
suitable to the American economy and health care system. The Department
of Commerce argues that Americans would benefit if OECD nations
eliminated their pharmaceutical price controls: the savings could amount to
an estimated $5 to $7 billion per year.336 Some analysts believe price
controls also decrease R&D spending and result in fewer new drugs,
particularly the most innovative drugs that have the greatest potential
benefit but may be costliest to produce.337
C. Government Price Negotiation under Medicare Part D
Federal price negotiation for prescription drugs is already taking place in
connection with FSS, VA, and 340B drug purchases. Medicare Part D is
currently barred by law from setting or negotiating drug prices, interfering
with negotiations between Part D plan sponsors and pharmaceutical
manufacturers, or establishing a formulary.338 Reforming Medicare Part D
to allow for government price negotiation or formulary restrictions may
lead to lower reimbursement rates for prescription drugs. However, the
government may retain the resulting decrease rather than passing it on to
Medicare beneficiaries in the form of lower premiums, deductibles, or cost
sharing or by shrinking the doughnut hole. The decrease could therefore
result in tax savings, but may not improve Medicare beneficiaries' access to
drugs.
A number of legislative proposals have been introduced to allow
Medicare Part D to negotiate drug prices and eliminate the doughnut
335. Id. In the U.S., some argue that changing a prescription drug to OTC status would
harm insured consumers by requiring them to pay the entire price out-of-pocket; such a
move is sometimes seen as an attempt by a pharmaceutical company to increase its market
by advertising the OTC status to consumers and thus avoiding the role of the prescriber and
the threat of State-mandated automatic generic substitution. The proposed Non-Prescription
Drug Modernization Act of 2007, H.R. 4038, 110th Cong. (1st Sess. 2007) and S. 2311,
110th Cong. (1st Sess. 2007) would (1) enhance the FDA's power to revoke authorization to
market a drug over-the-counter if it determines that doing so poses a risk to consumers, and
(2) expand the FDA's authority to regulate advertising of nonprescription drugs.
336. INT'L TRADE ADMN., supra note 331, at xi.
337. Carmelo Giacotto et al., Drug Prices and Research and Development Investment
Behavior in the Pharmaceutical Industry, 48 J.L. & ECON. 195, 211 (2005).
338. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003,
P.L. 108-173, § 1860D-11(h)(i)(1)-(2), 117 Stat. 2098 (2003) ("(i) NONINTERFERENCE.
-In order to promote competition under this part and in carrying out this part, the
Secretary-(1) may not interfere with the negotiations between drug manufacturers and
pharmacies and PDP sponsors; and (2) may not require a particular formulary or institute a
price structure for the reimbursement of covered part D drugs.").
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hole.339 The Medicare Prescription Drug Savings and Choice Act of 2009
would allow the government to negotiate Part D drug prices and create a
plan to compete with private plans under Part D.340
The government's reluctance to harness its regulatory tools and
bargaining power may have resulted in a considerable cost burden to
beneficiaries. 341 According to a Kaiser Family Foundation study, eighty-
five percent of adults would support the federal government's negotiating
with pharmaceutical companies for lower drug prices for Medicare
beneficiaries.342 A Congressional Research Service Report states that
harnessing the bargaining power of 43.7 million Medicare beneficiaries
might result in decreased pharmaceutical pricing, but CMS may lack the
track record and the bargaining strength of large PBMs, which cover even
larger populations.34 The Congressional Budget Office and the Chief
Actuary at CMS have determined that negotiations on behalf of Part D
beneficiaries might not exceed the price concessions achievable by private
plans.345 Moreover, such involvement on behalf of CMS may lead to a
restricted formulary that would decrease choice and drug availability for
Part D beneficiaries.346 The government's development of a Medicare Part
D formulary could lead to cost savings by directing prescribers and patients
toward lower-cost drug choices, by creating competition among drug
companies, and by intensifying the government's bargaining power.3 47
However, a restricted formulary can decrease quality of care 348 since
determining the formulary structure requires trade-offs involving cost
savings, patient preferences, and the properties of various drugs.
349
The Office of the Attorney General has alleged that Part D plan sponsors
overcharge beneficiaries and that the Centers for Medicare & Medicaid
Service (CMS) has failed to identify incidences of overpayments through
audits, resulting in an estimated $4.4 billion in overpayments in 2006
339. See S. 18, 109th Cong. (2005); S. 2240, 109th Cong. (2006); S. 2340, 109th Cong.
(2006); S. 2342, 109th Cong. (2006); H.R. 4, 109th Cong. (2006).
340. H.R. 684, 11 1th Cong. (2009) (enacted).
341. Davis & Collins, supra note 317, at 57.
342. KAISER SPOTLIGHT, supra note 29, at 19.
343. Jim Hahn, Cong. Research Serv., Federal Drug Price Negotiations: Implications
for Medicare Part D 10 (2007), http://lieberman.senate.gov/documents/crs/drugneg.pdf
344. Id at 11. Advance PCS, a large PBM, covers 75 million individuals; Medco Health
Solutions covers 65 million; Express Scripts covers 57 million.
345. Id. at 12.
346. Id.
347. Haiden A. Huskamp et al., The Impact of a National Prescription Drug Formulary
on Prices, Market Share, and Spending: Lessons for Medicare?, 22 HEALTH AFF. 149, 150
(2003).
348. Id. at 156.
349. Id. at 157.
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alone.350 Increased audits of Part D plan sponsors could produce cost
savings for plan participants without requiring the passage of additional
legislation.
Prescription drug costs for Part D beneficiaries could also be lowered
with the elimination of "reference-based pricing," a practice employed by
approximately ten percent of Part D plans.351 Reference-based pricing is
intended to encourage consumers to choose generic drugs: patients who
select a brand-name drug when a generic is available are typically charged a
price representing a co-pay plus the difference between the cost of the
brand-name drug and the generic.352 Although CMS now requires plan
sponsors to inform beneficiaries about the practice, the Plan Finder tool that
beneficiaries use to select a Part D plan does not always clearly identify
plans that use reference-based pricing.3 53 Reference-based pricing adds
complexity and potentially increases beneficiaries' drug costs in an attempt
to lower them. Eliminating the practice in favor of less punitive means of
encouraging generics could simplify Part D and lower the cost of
prescription drugs for beneficiaries of a Medicare prescription drug plan.
Similar to proposals for Medicare Part D negotiations, the proposed
United States National Health Care Act or the Expanded and Improved
Medicare for All Act would establish the United States National Health
Care (USNHC) Program, which would establish a formulary, negotiate
prices, and promote the use of generics as part of a scheme to provide
medically necessary health care to all residents of the United States.
354
D. Reforming Reimbursement Calculations for Part B Drugs
Medicare spending on Part B drugs increased from $3 billion in 1997 to
$11 billion in 2004, a 267 percent increase.355 During that same period,
overall Medicare spending rose 47 percent. 356 Medicare Part B reimburses a
limited number of pharmaceutical products that are generally administered
in a physician's office; many of these drugs are treatments for cancer.35
7
350. David Goldstein, Insurers Overcharged Medicare for Prescriptions, Report Finds,
MCCLATCHY NEWSPAPERS, Feb. 2, 2009, http://www.mcclatchydc.com/washington/story/
61200.html.
351. Jane Zhang & Vanessa Fuhrmans, Medicare Plans Draw Criticism on Drug
Pricing, WALL ST. J., Dec. 16, 2008, at D1.
352. Id.
353. Id.
354. United States National Health Care Act, H.R. 676, 111th Cong. § 205 (2009).
355. Catherine Arnst, Soaring Cancer Drug Costs May Cripple Medicare, BUS. WK.,
Jan. 27, 2009, available at http://www.businessweek.com/technology/content/jan2009/
tc20090127_588803.htm?chan--top+news-top+news+index+-+temptechnology.
356. Id.
357. See CTRS. FOR MEDICARE & MEDICAID SERVS., DEP'T OF HEALTH & HuMAN SERvs.,
Covered Medical and Other Health Services, in MEDICARE BENEFIT POLICY MANUAL § 50
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Newer cancer drugs are often priced at levels far in excess of the prices of
older drugs:
Most of the newest treatments are taken along with older chemotherapies,
and some are even taken in combination with one another, adding pricey
drug on top of pricey drug. Dr. Leonard Saltz of Memorial Sloan-
Kettering Cancer Center in New York says that 10 years ago the drugs
used to treat colon cancer cost about $500. Today, the tab is $250,000.
Over the same 10-year period, the average life expectancy for colon
cancer patients increased from 11 months to a little more than two years.
"We're excited about these drugs," he says, "but not everyone can get
them. Something has to give."
358
The newer drugs are patented and tend to have little competition from
"me-too" drugs, so manufacturers have no incentive to lower prices. Some
patients are willing to mortgage their homes to obtain the drugs, while
others refuse treatment because they are unable to afford them.359
Reimbursement under Medicare Part B was reformed to use the ASP
benchmark rather than AWP.36° Current reimbursement levels are pegged at
106 percent of ASP for most Part D drugs.361 The Secretary of Health and
Human Services conducted a study on sales of Part D drugs and biologicals
to determine whether prices paid by large volume purchasers (such as
PBMs and Health Maintenance Organizations (HMOs)) are representative
of the prices a prudent physician pays for the drugs.362 The purpose of the
study was to determine whether sales to such purchasers should be excluded
from ASP calculation.363 The Secretary was unable to complete the analysis
because manufacturers refused to provide ASP data by type of purchaser
due to the proprietary nature of this data.364 The Secretary concluded that
physicians are generally able to obtain the drugs at prices below the
reimbursement rate.365 The study did not determine whether Medicare and
beneficiaries were overcharged for the drugs.
Reforming the cost of Part B drugs could involve the imposition of
revised pricing benchmarks. Legislation introduced in the U.S. Senate in
(2009), http://www.cms.hhs.gov/Manuals/downloads/bp102c15.pdf.
358. Catherine Arnst, Going Broke to Stay Alive, Bus. WK., Jan. 30 2006, available at
http://www.businessweek.com/magazine/content/06 05/b3969051 .htm.
359. Id.
360. MICHAEL 0. LEAVITT, DEP'T OF HEALTH & HUMAN SERVS., REPORT TO CONGRESS
REPORT ON SALES OF DRUGS AND BIOLOGICALS TO LARGE VOLUME PURCHASERS 2 (2006),
http://www.cms.hhs.gov/reports/downloads/LVPRTC 2 09_06.pdf.
361. Id.
362. Id.
363. Id.
364. Id.
365. Id. at 5.
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2006 proposed assuring that Medicare reimbursement for outpatient cancer
drugs does not exceed or fall short of actual ASP for such drugs.366 The
legislation further proposed continuing demonstration projects to assess
oncology services and the development of quality indicators to evaluate
oncology care.367
To determine which cancer treatments may be reimbursed under Part B,
CMS relies on compendia.368 Critics argue some compendia have financial
ties to the pharmaceutical industry and that a compendium's inclusion of a
drug for a specific application may not be supported by substantial clinical
evidence.369
Peter B. Bach, M.D., M.A.P.P., has proposed establishing a Center for
Comparative Effectiveness that would evaluate clinical research to
determine which cancer drugs are superior and which are
interchangeable. 370 Based on these results, some cancer drugs may qualify
as multi-source drugs which would enable Medicare to lower
reimbursement by calculating payment under rules for blended
reimbursement., 3
71
The findings of a Center for Comparative Effectiveness could also
provide the basis for payment using a "least costly alternative" calculation,
which would enable Medicare to reimburse a drug at the price of the least
expensive interchangeable drug.372 However, implementing a least costly
alternative calculation would require legislation, as the U.S. District Court
for the District of Columbia has held that the Secretary of Health and
Human Services lacks the authority to implement these reimbursement
rates.373
A first step toward decreasing the cost of cancer drugs through
366. S. 2340, 109th Cong. § 2 (2006).
367. S. 2340, §§ 3-4.
368. See Katherine Tillman et al., Compendia and Anticancer Therapy Under Medicare,
150 ANNALS INTERNAL MED. 348, 348 (2009), available at http://www.annals.org/
cgi/reprint/150/5/348.pdf. "In the pharmaceutical industry, a compendium is a
comprehensive listing of drugs and biologicals. It typically includes a summary of the
pharmacologic characteristics of each listed drug or biological; information on dosage; and,
often, recommended uses for specific diseases. Some insurers refer to compendia when
making policy decisions, thus creating a strong financial incentive for manufacturers to
obtain a favorable compendium recommendation. The Fee-for-Service Medicare program
recognizes certain published compendia as authoritative references to identify medically
accepted, unlabeled uses of drugs and biologicals in anticancer treatment regimens."
369. Reed Abelson & Andrew Pollack, Medicare Widens Drugs It Accepts for Cancer
Care, N.Y. TIMEs, Jan. 27, 2009, at Al.
370. Peter B. Bach, Limits on Medicare's Ability to Control Rising Spending on Cancer
Drugs, 360 NEw ENG. J. MED. 626, 632 (2009).
371. Id.
372. Id. at 627.
373. Hays v. Leavitt, 583 F. Supp. 2d 62, 68 (D.D.C. 2008).
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comparative effective analysis may be the result of the $1.1 billion allocated
for researchers to compare various medical treatments for the same illness
under the recent economic stimulus bill.374 Other nations, including France
and the U.K., attempt to decrease health care costs by discouraging the use
of ineffective treatments; both nations have bodies that assess various
medical treatments to compare their effectiveness and sometimes their
costs.
375
Critics, including lobbyists for the pharmaceutical industry, are
concerned that research findings will be used to deny coverage or ration
care and that it could allow government to intrude on the physician-patient
relationship.376 Some women and minority groups have expressed concerns
that the research may not identify differences in the response to treatment
options that are specific to gender or ethnicity.
3 77
Supporters of the initiative include consumer groups, unions, large
employers, and pharmacy benefit managers who anticipate the program will
provide needed information to physicians and patients.3 78 Cost effectiveness
analysis may give drug companies an incentive to compile effectiveness
data of their own, potentially increasing research, development, and testing
costs which would in turn increase the price of their products.379
E. Regulating Pharmaceutical Companies'Promotional Activities
Efforts to reform drug company marketing practices are based in part on
the notion that industry-wide restrictions will enable companies to realize
savings in the form of decreased marketing budgets, and that such savings
will be passed along to consumers in the form of lower price reductions.
Individual drug companies may be reluctant to risk the competitive
disadvantage of decreasing marketing activities without such uniform
regulation. In addition, reform efforts designed to curb certain practices,
such as direct-to-consumer advertising and the gifts and payments drug
companies offer prescribing physicians, aim to suppress the impact of these
practices on physician and patient behavior.
374. Pear, U.S. to Study Effectiveness, supra note 239, at Al.
375. Id.
376. Id. See also Emily Waltz, Comparative Effectiveness Casts First Shadows Across
U.S. Industry, 27 NATURE BIOTECHNOLOGY 211, 211 (2009).
377. Pear, U.S. to Study Effectiveness, supra note 239, at Al.
378. Id.
379. For an analysis of the pharmaceutical industry's possible response to
pharmacoeconomic analysis, see generally STEVEN SEGET, Bus. INSIGHTS, PHARMACEUTICAL
PRICING STRATEGY: OPTIMIZING RETURNS THROUGHOUT R&D AND MARKETING (2003).
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1. Direct-to-Consumer Advertising
Direct-to-consumer (DTC) pharmaceutical advertising, which is
prohibited in many European countries, 3 80 is used in the U.S. to increase
awareness of, and the size of the market for, prescription drugs.
Representative Henry A. Waxman supports legislation that would enable
the FDA to ban selected DTC advertising during a drug's initial years on
the market, which tend to be the period of most aggressive marketing for a
prescription drug.381 Waxman points to the risk that advertising may expose
more consumers to side effects that do not become apparent until a drug has
been on the market for a period of time. 382 Promotional expenses, which
may exceed the cost of R&D for pharmaceutical manufacturers,383 increase
pharmaceutical manufacturers' costs.
2. Marketing Disclosure Legislation
Critics of the pharmaceutical industry have argued that gifts, payments to
physicians, and fees to physicians who consult or speak on behalf of drug
companies' products influence prescribing behavior, which could induce
physicians to prescribe a drug that is not the most cost-effective for a
patient. 384 The drug industry spent over $6.8 billion on logo items, meals,
380. Rosenthal, supra note 265.
381. Connolly, supra note 234.
382. Id.
383. Marc-Andr6 Gagnon & Joel Lexchin, The Cost of Pushing Pills: A New Estimate of
Pharmaceutical Promotion Expenditures in the United States, 5 PLoS MED. 0029, 0032
(2008), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174966/pdf/pmed.0050001 .pdf.
384. See Eric G. Campbell, Doctors and Drug Companies-Scrutinizing Influential
Relationships, 358 NEw ENG. J. MED. 1796, 1796 (2007). "From a policy perspective, the
debate centers on the overall effect of these relationships [physician relationships with the
pharmaceutical industry] on patient care. Although most physicians deny that receiving free
lunches, subsidized trips, or other gifts from pharmaceutical companies has any effect on
their practices, research has shown that physician-industry relationships do influence
prescribing behavior. After all, if these relationships didn't affect physician behavior in such
a way as to increase sales, companies wouldn't spend $19 billion each year establishing and
maintaining them." See also Paid to Prescribe? Exploring the Relationship Between Doctors
and the Drug Industry: Hearing Before the S. Comm. on Aging, 110th Cong. 23-24 (2007)
(prepared statement of Peter Lurie, Deputy Director, Public Citizen's Health Research
Group). "Pharmaceutical marketing to physicians includes free samples, promotional
detailing, and continuing medical education activities, and has been shown to alter physician
behavior .... [C]ontact with pharmaceutical company representatives is associated with
changes in the prescribing practices of residents and physicians and more rapid adoption of
new drugs by prescribers. Sponsorship of continuing medical education programs by a
pharmaceutical company and all-expenses-paid travel to conferences are associated with
increases in the prescribing rate of the sponsor's drugs. Finally, interactions with a
pharmaceutical company representative are associated with an increased likelihood of
requesting that the representative's company's drugs be added to the hospital formulary."
See also Kirby Lee, Has the Hunt For Conflicts of Interest Gone Too Far?, 366 BRIT. MED.
J. 477, 477 (2008). "[R]esearch in social science shows that gifts of any size from drug
49
Tironi: Pharmaceutical Pricing: A Review of Proposals to Improve Access a
Published by LAW eCommons, 2010
Annals of Health Law
and office visits, according to a 2005 report in the New England Journal of
Medicine. 85
Several states have enacted legislation mandating pharmaceutical
company disclosure of gifts and payments to physicians and other
providers, and proposed federal legislation would require such disclosure as
well.386 Critics argue that existing state legislation has been ineffective
either because: (1) it may lack enforcement mechanisms; (2) the
information gathered is not available in a form that is conveniently
accessible to the public; and (3) pharmaceutical company information
387
submitted as "trade secrets" are withheld from public scrutiny.
Members of the Pharmaceutical Research and Manufacturers of America
(PhRMA), a trade association for the prescription drug industry, announced
the voluntary adoption of a marketing code 388 under which about forty
companies agree to no longer distribute free products with product logos to
doctors and nurses. The code also restricts the meals pharmaceutical
companies may purchase for physicians. 389 BIO (the Biotechnology
Industry Organization), a trade group for biotechnology, has not adopted
the advertising code.
390
The American Medical Association (AMA),391 the American College of
Physicians, and the American Society of Internal Medicine have all adopted
additional voluntary codes to serve as guidelines.392 The HHS Office of
Inspector General issued a Compliance Program Guidance for
Pharmaceutical Manufacturers.393 In spite of the existence of these codes
and guidelines, promotional practices of pharmaceutical companies
continue to receive harsh criticism and scrutiny.
394
companies create feelings of obligation and reciprocity."
385. Connolly, supra note 234.
386. Robert Steinbrook, Disclosure of Industry Payments to Physicians, 359 NEW ENG.
J. MED. 559, 559-60 (2008).
387. Joseph S. Ross et al., Pharmaceutical Company Payments to Physicians: Early
Experiences with Disclosure Laws in Vermont and Minnesota, 297 J. AM. MED. Ass'N 1216,
1221 (2007).
388. PHARM. RES. & MFRS. OF AM., CODE ON INTERACTIONS WITH HEALTHCARE
PROFESSIONALS 3 (2009), http://www.phrma.org/files/PhRM A%2OMarketing%2OCode%
202008.pdf.
389. Connolly, supra note 234.
390. Id.
391. AM. MED. Ass'N, Opinion 8.061 Gifts to Physicians from Industry, in CODE OF
MEDICAL ETHICS (2009), available at http://www.ama-assn.org/ama/pub/physician-
resources/medical-ethics/code-medical-ethics/opinion8061.shtml.
392. Ross et al., supra note 387, at 1217.
393. OIG Compliance Program Guidance for Pharmaceutical Manufacturers, 68 Fed.
Reg. 23731 (May 5, 2003).
394. See Barry Meier & Benedict Carey, Drug Maker is Accused of Fraud, N.Y. TIMES,
Feb. 26, 2009, at B1. See also Duff Wilson, Patching a Wound, N.Y. TIMES, Mar. 3, 2009, at
BI.
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A further method to influence drug prices by controlling pharmaceutical
promotional activities involves restricting pharmaceutical company access
to doctor-prescription drug data. Drug company representatives may use
such information to target doctors for pharmaceutical industry perks or to
direct promotional efforts to encourage certain doctors to prescribe more
expensive drugs.395 A federal appeals court in Boston recently held that
states have the right to prohibit the sale of such data in order to control state
health care costs. 3 96 The lead sponsor of New Hampshire legislation
prohibiting the sale of prescriber data was motivated in part by concern that
state Medicaid costs were inflated due to the pharmaceutical industry's
coaxing doctors to prescribe brand-name drugs.
397
F. Compulsory Licensing or Auctioning of Patents
In their 2008 book, Reasonable Rx: Solving the Drug Price Crisis, Stan
Finkelstein and Peter Temin propose a scheme to overhaul the
pharmaceutical industry on a scale comparable to that implemented in the
telecommunications industry with the break-up of AT&T.398 The authors
propose de-integrating the pharmaceutical industry, splitting each
corporation into an R&D firm and a manufacturer/marketing (M&M)
firm.3 99 A new federal agency, the Drug Development Corporation (DDC)
would broker drug patents by auctioning exclusive rights to the M&M firms
on behalf of the R&D owner.400 Critics argue that the plan would preclude
competition and would dismantle a major American industry that "has no
peer in the world for bringing new drugs into the market."4 1 An additional
concern is the challenge of conducting an informed auction for a newly
patented drug for which there is no market experience. 402 The Finkelstein
proposal is similar to a plan proposed by economist Michael Kremer which
would allow the government to purchase pharmaceutical patents for a sum
sufficient to reimburse R&D investment and sell the patents in competitive
markets in order to increase the availability of new pharmaceuticals while
395. Stephanie Saul, Doctors Object to Gathering of Drug Data, N.Y. TIMES, May 4,
2006, at Al.
396. Associated Press, New Hampshire: Ruling on Prescriptions, N.Y. TIMES, Nov. 19,
2008, at A23.
397. Warren Ross, The Battle of New Hampshire, MED. MARKETING & MEDIA, Nov.
2006, at 60, 61 (2006), http://www.imshealth.com/deployedfiles/imshealth/Global/Content/
StaticFile/New_Hampshire/heBattleofNewHampshire.pdf.
398. Peter Stein, First, Do No Harm, 27 HEALTH AFF. 1736, 1736 (2008) (reviewing
STAN FINKELSTEIN & PETER TEMIN, REASONABLE Rx: SOLVING THE DRUG PRICE CRISIS
(2008)).
399. Id.
400. Id.
401. Id.
402. Id. at 1737.
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supporting and compensating R&D efforts.4 °3
An alternative proposal would permit the U.S. government to issue
requests for grant proposals from public and private institutions to research
pharmaceutical drugs and to retain any patents generated. 40 4 The
government would then license the patents free of charge to any competent
producer.40 5 The goal of the proposal is to lower drug prices and redirect
R&D to achieve greater public welfare.40 6
A bill to overhaul patent litigation was recently introduced in the U.S.
Senate that would award damages for patent infringement by imposing a
reasonable royalty or requiring the infringer to reimburse the patent holder
for profits lost.40 7 The Coalition for 2 1st Century Patent Reform has
criticized the proposal, stating that it would permit patented technology to
be copied without consequence.4 8
CONCLUSION
The pharmaceutical industry, particularly when analyzed on a global
scale, is a complex web of competing interests that interact to research,
develop, regulate, promote, market, prescribe, and utilize prescription drugs
for the treatment of human disease. Individuals who are unable to access or
afford needed medications may face preventable pain, disability,
unemployment and other economic losses, and even death.
The complexity of the American health care market makes it difficult to
improve accessibility across the board because various consumers are
affected by different programs, plans, and policies. Some receive their
prescription medications under various federal programs such as Medicare,
Medicaid, 340B, FSS, or the VA. Others have private insurance through an
employer that may or may not cover prescription drugs, and those that do
often impose cost sharing measures that require consumers to spend out-of-
pocket for their medications. The uninsured, who have no program or plan
to negotiate drug prices on their behalf, often pay the highest prices of all,
and are the most likely to go without needed medication, a situation with a
disproportionate impact on the poor, elderly, and chronically ill.
A wide variety of reform proposals are currently being debated to
403. Douglas Gary Lichtman, Pricing Prozac: Why the Government Should Subsidize
the Purchase of Patented Pharmaceuticals, 11 HARV. J.L. & TECH. 123, 123-24 (1997).
404. Peter Stein & Ernst Valery, Competition: An Antidote to the High Price of
Prescription Drugs, 23 HEALTH AFF. 151, 154, 158 (2004).
405. Id. at 154.
406. Stein, supra note 398, at 1737.
407. William McQuillen, Patent Bill Pushed to Boost Economy, Lawmakers Say,
BLOOMBERG, Mar. 3, 2009, http://www.bloomberg.com/apps/news?pid-20670001 &refer=&
sid=arhhfAyJxN4w.
408. Id.
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remedy the problem of drug access in America. Some advocate reforming
patent laws to make patented pharmaceutical innovations more widely
accessible to manufacturers, to facilitate the development and marketing of
generic biotechnology drugs, or to restrict pharmaceutical companies'
ability to employ follow-on drugs and product-hopping. Other proposals
would promote the use of generics by restricting "authorized generics" or
educating consumers or providers as to the availability and advantages of
generic drugs. Others aim to encourage competition by preventing brand-
name companies from settling infringement litigation with generics
manufacturers that would delay generics market entry and perpetuate brand-
name monopoly profits.
Proposals to import pharmaceuticals from abroad indirectly benefit from
the pharmaceutical pricing regulations of other industrialized governments.
Importation proposals risk the introduction of counterfeit drugs into the
American health care system, as well as drugs whose safety is compromised
due to improper storage or expiration. As an alternative to importation, the
U.S. could adopt selected price regulation strategies that have been tested in
other developed nations. For example, price negotiations for prescription
drug plans under Medicare Part D could result in savings for elderly and
disabled Americans. Reforming reimbursement calculations for Medicare
Part B drugs, which include many expensive cancer treatments, could lead
to important price reductions.
Reform proposals that attempt to restrict or direct the behavior of
pharmaceutical manufacturers (for example, by restricting settlement
negotiations or prohibiting certain promotional activities or mandating their
disclosure), risk being thwarted by the industry's ability to respond
strategically to challenges that arise in the market, economic, technical, and
regulatory environments.
Americans who need but cannot afford prescription drugs would benefit
most, and in the least amount of time, from proposals to educate consumers
about the generics choices that are already available but underutilized and a
program to inform physicians about cost effectiveness for prescription
pharmaceuticals. A public relations campaign for consumers and academic
detailers to provide physicians information on the cost effectiveness of
competing treatment options and the availability of generic or other lower
cost drug choices would decrease prescription drug costs and promote
generics acceptance and use.
Promoting chain pharmacy generics discount programs could also help
consumers access affordable drugs. Helpful reforms could include
exempting such discount programs from predatory pricing or unfair
competition laws and mandating that they not discriminate against
Medicare Part D beneficiaries. Informing consumers about prescription
assistance programs that are already in place could lead to the programs'
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increased utilization, thereby enhancing access and affordability. Improving
the Medicare Part D Plan Finder tool to facilitate beneficiary understanding
of plan options, such as tiers and reference-based pricing, could help
Medicare beneficiaries better afford their prescriptions.
The patent cliff will soon enable generics manufacturers to produce
versions of name-brand drugs without the burden of Hatch-Waxman patent
litigation and the potential for an FTC challenge of any resulting settlement.
The greatest threat to the availability of generics that will result from the
patent cliff is the potential for innovators to develop follow-on drugs,
engage in product-hopping (particularly if the original brand-name version
will be discontinued to thwart state mandatory substitution laws), and
market authorized generics, which can discourage generics entry by making
any "unauthorized" generic a second or subsequent market entry. A reform
proposal to prevent innovators from discontinuing original formulations and
from marketing authorized generics could lead to improvements in
pharmaceutical access and affordability through the availability of generic
versions of brand-name drugs that lose patent protection during the next
seven years. As an alternative or complement to such an initiative, generics
manufacturers who must undertake promotional campaigns due to
discontinuation of the brand-name equivalent could be permitted to utilize
academic detailers to deliver information about their product's availability.
Direct-to-consumer innovator advertising could be regulated to prevent its
impairing the effectiveness of a consumer-oriented education campaign.
Biotech generics have the potential to benefit consumers through lower
prices (although savings are unlikely to be as great as those provided by
generic pharmaceuticals). However, legislative, regulatory, and technical
hurdles and the absence of a patent cliff for biotech drugs will delay the
benefits of the proposed legislation.
Attempting more broad-based patent law reform to lower drug prices
would involve a massive undertaking with myriad consequences that will
affect not only the pharmaceutical industry but related industries throughout
the supply chain, as well as unrelated industries that rely heavily on patent
protection, such as electronics technology. The complexity and delay
inherent in crafting and implementing broad patent law reforms render such
reforms unlikely to help a significant number of consumers better afford
their prescription drugs in the near future.
Reform proposals to allow Medicare Part D price negotiations, formulary
development, and to reform reimbursement calculations for Part B drugs
could save taxpayer dollars, but these savings may not benefit consumers in
the form of substantially lower drug prices. Inter-agency cooperation would
maximize bargaining power and provide negotiation expertise: such a
scheme would draw on the experience of agencies that administer the VA,
FSS, and 340B programs and would concentrate the massive purchasing
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power of the federal government through the combination of the currently
fragmented federal drug-purchasing programs.
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